Background
Nangibotide (LR12) peptide is a specific TREM-1 inhibitor. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved survival. In phase I, nangibotide was found to be safe and well tolerated up to the highest dose (6 mg/kg/h).

Materials and methods
International, multi-center phase IIa randomized, double-blind, two-stage, placebo-controlled study (NCT03158948). Main inclusion criteria were septic shock according to Sepsis 3 definition and nangibotide to be initiated within 24 hours of shock onset. Patients were randomized to receive either placebo, 0.3, 1 or 3 mg/kg/h of nangibotide. Stage-1 investigations were performed on the first 24 hours of nangibotide administration (4 patients in each group), and stage-2 investigations on the first 24 hours after the end of stage 1 (12 patients in each group). Study drug was infused until end of study. Primary endpoint was non-inferiority safety and tolerability. Patient follow-up period was 90 days.

Results
50 patients were randomized and 49 treated (1 patient died before dosing). All groups were well balanced in terms of baseline characteristics, except for APACHE II score which tend to be non-significantly lower in placebo group. Primary infection source was abdominal, pulmonary and urinary (40%, 50% and 10% respectively). A trend toward a decrease in circulating levels of endothelium injury markers was observed in nangibotide-treated patients.

Conclusion
Nangibotide was shown to be safe and well tolerated in septic shock patients. Although this small exploratory study was not powered to conclude on efficacy, a signal with non significant lower mortality was observed in the nangibotide group. These results support the need of a larger study to demonstrate the role of nangibotide in the treatment of septic shock.

Table 1 (abstract P1). Treatment emergent adverse event and serious adverse event

| Patients with at least one adverse event | Placebo N=12 | 0.3 mg/h N=13 | 1.0 mg/h N=12 | 3.0 mg/h N=12 | Total N=49 |
|----------------------------------------|-------------|---------------|---------------|---------------|-----------|
| TEAE (n=49)                            |             |               |               |               |           |
| TEAE related to the study drug         | 10 (83.3%)  | 12 (92.3%)    | 12 (100.0%)   | 11 (91.7%)    | 45 (91.8%)|
| Severe TEAE                            | 8 (66.7%)   | 6 (46.2%)     | 5 (41.7%)     | 4 (33.3%)     | 23 (46.9%)|
| TEAE related to the study drug         | 2 (16.7%)   | -             | -             | -             | 4 (8.2%)  |
| Serious AE incl. death                 | 7 (58.3%)   | 4 (30.8%)     | 2 (16.7%)     | 4 (33.3%)     | 17 (34.7%)|

Table 2 (abstract P1). Vasopressors and ventilator free days

| Days alive and free of IMV (min/max) | Placebo N=12 | 0.3 mg/h N=13 | 1.0 mg/h N=12 | 3.0 mg/h N=12 | Total N=49 |
|--------------------------------------|-------------|---------------|---------------|---------------|-----------|
| Vasopressors median (min/max)        | 25.5 (0/35) | 25.0 (0/33)   | 25.5 (0/31)   | 23.0 (0/28)   | 24.0 (0/35)|
| IMV median (min/max)                 | 24.0 (0/36) | 22.0 (0/35)   | 25.5 (0/30)   | 24.0 (0/36)   | 23.0 (0/36)|

P2
Difference of lactate level for predict mortality between cirrhosis and non-cirrhosis septic shock patient
Surat Tongyoo, Thavinee Trainarongsakul, Tanuwwong Varasilpa, Chairat Permpikul
Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Correspondence: Surat Tongyoo (surat.ton@mahidol.ac.th)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P2

Background
Serum lactate is an important marker of tissue perfusion. Impaired hepatic function especially among cirrhosis patients could decrease lactate elimination and result in higher lactate level during septic shock. Whether serum lactate level could be used to predict outcome of cirrhosis patients with septic shock had not been identified. This study was thus aimed to evaluate the utility of serum lactate to predict mortality, comparing between cirrhosis and non-cirrhosis septic shock patients.
From 777 enrolled septic shock patients, 91 were previously diagnosed cirrhosis. The primary outcome was hospital mortality. Results

From 777 enrolled septic shock patients, 91 were previously diagnosed cirrhosis. The patients' age, gender, baseline arterial pressure and severity score were not different between cirrhosis and non-cirrhosis patients. Cirrhosis patients had significant higher body mass index, lower temperature and slower heart rate. Baseline serum lactate and at shock reversal were significantly higher in cirrhosis patients (baseline, 7.5±6.1 vs 4.3±3.7 mmol/L; P<0.001 and at shock reversal 4.5±4.1 vs 3.2±3.0 mmol/L; P=0.01). Lactate clearance was not different (27.3±24.7 vs 23.5±21.5 percent; P=0.35) and so was hospital mortality (36.3% in cirrhosis vs 30.1% in non-cirrhosis; P=0.23). The receiver operating characteristic (ROC) curve analysis identifies that baseline lactate is the most reliable prognostic factor for hospital mortality according to the area under the curve (AUC). (Table 1) The cut-off point to predict hospital mortality was 5 mmol/L for cirrhosis and 4 mmol/L for non-cirrhosis patients.

Conclusions

Baseline serum lactate in cirrhosis septic shock patients was higher than non-cirrhosis patients. The cut-off point of baseline lactate to predict hospital mortality was 5 mmol/L and 4 mmol/L among cirrhosis and non-cirrhosis septic shock patients.

References

1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-377.

Table 1 (abstract P2). ROC curve analysis identify cut-off point of lactate to predict hospital outcome

| Parameter          | AUC(95%CI) | Cut-off point | Sensitivity | Specificity | Youden's index |
|--------------------|-----------|---------------|-------------|-------------|----------------|
| Non-cirrhosis      | 0.63(0.57-0.66) | 4 | 0.5 | 0.66 | 0.16 |
| -Baseline lactate  |           |               |             |             |                |
| -Following lactate | 0.62(0.56-0.68) | 2 | 0.8 | 0.44 | 0.24 |
| -Lactate clearance | 0.56(0.50-0.62) | 10 | 0.7 | 0.43 | 0.13 |
| Cirrhosis          | 0.65(0.64-0.85) | 5 | 0.78 | 0.61 | 0.39 |
| -Baseline lactate  |           |               |             |             |                |
| -Following lactate | 0.60(0.35-0.84) | 5 | 0.67 | 0.68 | 0.35 |
| -Lactate clearance | 0.54(0.29-0.78) | 20 | 0.52 | 0.56 | 0.08 |

Table 1 (abstract P3). Multivariate analysis for predictive factor associated with 30-day mortality

| Parameter          | Relative risk | 95% confidence interval | P value |
|--------------------|---------------|-------------------------|---------|
| Age ≥ 80 years old | 2.23          | 1.01-4.96               | 0.05    |
| Cirrhosis          | 5.05          | 1.91-13.38              | 0.001   |
| Pneumonia          | 2.00          | 1.01-4.05               | 0.05    |
| Positive hemoculture | 3.10       | 1.46-6.55               | 0.003   |
| Ventilator support | 4.91          | 2.29-10.55              | <0.001  |
| Adrenaline requirement | 3.02   | 1.11-8.20               | 0.03    |

P3

Septic shock outcomes among octogenarians

Chairat Permpikul, Surat Tongyoo
Division of Critical Care Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Correspondence: Surat Tongyoo (surat.ton@mahidol.ac.th)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P3

Background

Thailand is moving toward aged society. It is interesting whether octogenarian elderly aged 80 years old or older with septic shock has different clinical characteristics and outcomes as compared with younger patients. We report here the information from our patient cohort.

Materials and methods

This is a retrospective study, included adult septic shock patients who were admitted at Siriraj hospital between April 2011 and December 2017. Patients’ baseline information, severity score, treatment modality and outcomes were retrieved. Octogenarian was defined by the age of 80 years or older at the day of admission. All patients received septic shock resuscitation, following standard guideline.1 The primary outcome was 30 days mortality.

Results

A total of 782 septic shock patients were enrolled. Of these 133 were 80-year-old or older. When compared with younger patients, octogenarian had lower APACHE II score and higher comorbidities which included: hypertension, coronary artery disease, previously stroke, cirrhosis, and chronic kidney disease. Pneumonia was the leading site of infection in both groups but occurred in higher proportion in octogenarian (46.6% vs 29.7%, P 80 years old as the independent predictor of death within 30 days, as well as other parameters as shown in Table 1.

Conclusions

Octogenarian with septic shock had lower disease severity but higher comorbidities. This group had higher mortality, both at 30 day and at discharge.

References

1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-377.

P4

Effect of low dose corticosteroid in septic shock resuscitation: subgroup analysis result of a randomized controlled trial

Surat Tongyoo, Chairat Permpikul
Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Correspondence: Surat Tongyoo (surat.ton@mahidol.ac.th)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P4

Background

Efficacy of low dose hydrocortisone administrated during septic shock resuscitation had been long debated. Despite recent two large randomized controlled trials, steroids benefit is still inconclusive [1,2]. The aim of this study is to evaluate the effect of hydrocortisone on resuscitation outcomes, comparing between hydrocortisone and placebo.

Materials and methods

This is a retrospective study, included participants who were enrolled in the previously reported randomized controlled trial of hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome [3]. The patients who met criteria of septic shock, according to Sepsis-3 definition [4] were included in sub-group analysis. The treatment group received hydrocortisone 50 mg intravenously every 6 hours for 7 days, while the control group received normal
saline in identical volume. The primary outcome was rate of survival without organ support at 28 days after septic shock diagnosis.

Results
Of 197 patients enrolled in the previous study, 154 patients met septic shock criteria. Seventy-eight patients were in the placebo group. The patients’ age, gender, underlying conditions, source of infection, baseline arterial pressure and severity score were not different. Mean APACHE II score was 22.3±5.8, mean SOFA score was 11.6±3.1 and mean initial lactate was 4.0±2.4 mmol/L. The rate of survival with no organ support at 28 days was non-significantly higher in hydrocortisone group (61.5% vs 48.7%, relative risk 1.28 [95%CI 0.93-1.76]; P=0.12). The secondary outcomes, as shown in Table 1, were not different; except vasopressor dependent day which was shorter in hydrocortisone group (4.8±3.0 vs. 6.8±5.7 days; P=0.008). As for adverse events, hyperglycemia occurred more in hydrocortisone group (83.8% vs. 68.9%; P=0.03) while the rate of re-infection, cardiac arrhythmia and gastrointestinal bleeding was the same.

Conclusions
Hydrocortisone administration during septic shock resuscitation associated with shorter vasopressor dependent day without any benefit in other outcomes.

References
1. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Carioi A, Forceville X, Schwebel C, Martin C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. New Engl J Med 2018, 378: 809–818.
2. Venkatnath B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Corea M, Glass P, Harward M, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018, 378:797–808.
3. Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kokac M, Meduri G. Hydrocortisone treatment in early sepsis associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 2016, 20: 329.
4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315: 801–810.

Table 1 (abstract P4). Primary and secondary outcome comparing between hydrocortisone and placebo groups

| Outcome                                      | Placebo (n=76) | Hydrocortisone (n=78) | Relative Risk (95%CI) | P      |
|----------------------------------------------|----------------|-----------------------|-----------------------|--------|
| Primary outcome: Survive with no organ support at 28 day (%) | 37 (47.7)     | 48 (61.5)             | 1.28 (0.93-1.76)      | 0.12   |
| Secondary outcome: 28 day mortality (%)      | 24 (31.6)     | 19 (24.4)             | 0.78 (0.59-1.18)      | 0.32   |
| Hospital mortality (%)                       | 35 (46.1)     | 33 (42.3)             | 0.93 (0.67-1.33)      | 0.64   |
| Ventilator dependent days                    | 14.6±9.3      | 12.0±8.0              | 0.07                  |        |
| Days survive without ventilator in 28 days   | 9.2±9.7       | 12.1±9.4              | 0.07                  |        |
| Vasopressor dependent days                   | 6.8±5.7       | 4.8±3.0               | 0.008                 |        |
| Days survive without vasopressor in 28 days  | 17.1±9.4      | 19.3±8.5              | 0.12                  |        |
| Renal replacement therapy (%)                | 19 (25)       | 21 (26.9)             | 1.05 (0.70-1.57)      | 0.79   |
| RRT dependent days                           | 2.1±4.3       | 2.1±4.8               | 1.0                   |        |

P5
THAI-ICU score as a simplified severity score for critically ill patients: result from SEA-AKI study group

Theerapan Sukmark1, Kerkait Praditpoomsilpa2, Kriang Tungsang2, Kamol Khostrangskun1, Pitchdee Oranpisupak1, Somchai Eiam-ong2, Nattachai Sirisawat2,3
1Thungsong Hospital, Nakhon Si Thammarat, Thailand; 2Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Maharaj Nakhon Si Thammarat hospital, Nakhon Si Thammarat, Thailand; 4Nan hospital, Nan, Thailand; 5Excellence Center for Critical Care Nephrology, Thai Red Cross, Bangkok, Thailand

Correspondence: Theerapan Sukmark (theerapan_s@hotmail.com) Intensive Care Medicine Experimental 2018, 6(Suppl 1):P5

Background
Intensive care unit (ICU) scoring systems is commonly used worldwide to predict ICU outcome. However, most of standard scores usually need many variables, even some sophisticated laboratory parameters or software to calculate. In resource limited setting, this is one of the major barriers to apply in clinical practice. The objective of this study was to create a simplified ICU scoring system to predict mortality in critically ill patients.

Materials and methods
A prospective multicenter website-based-data-collection cohort, involving the adult patients who admitted to ICU of 17 centers across Thailand during 2013 to 2015. A development cohort and a validation cohort were randomly selected from available enrollment data. The simplified score was created by multivariable regression-based method. Receiver-Operating Characteristic (ROC) analysis was used for evaluating discrimination performance[1]. Hosmer-Lemeshow (H/L) - C statistic and calibration curve were performed to calibration evaluation[2].

Results
In development cohort: 3,458 cases were in analysis. Among those, 2,458 (71 %) and 1,000 (29 %) cases were alive and dead in hospital course, respectively (Fig. 1). Adjusted odds ratios (95% CI) of predictors including low Glasgow coma score (GCS 10-14), very low GCS (<10), low blood pressure (Mean arterial pressure < 70 mm Hg or need vasopressor), over positive net fluid balance (>1,500 cc), tachypnea (respiratory rate > 24 per minute), low platelet count (<150,000 / µL), and high BUN (BUN > 20 mg/dL) were 4.2 (3.1-5.6), 12.9 (9.4-17.8), 2.3 (1.9-2.8), 1.3 (1.1-1.6), 1.6 (1.3-1.9), 1.9 (1.6-2.3), and 1.8 (1.5-2.2), respectively (Fig. 2). In simplified THAI-ICU score (6 variables) model, the scores of those predictors were 4, 13, 2.5, 1.5, 1.5, 2, and 2, respectively (Table 1). In validation cohort of THAI-ICU score model (6 variables); 1,880 cases were in analysis. The AUC (95%CI) of THAI-ICU, APACHE II, and SOFA score were 0.81 (0.78-0.83), 0.76 (0.74-0.79), and 0.77 (0.75-0.80), respectively (Fig. 3).

For discrimination evaluation, at the cutoff value equal to 9 of THAI-ICU score; the sensitivity, specificity, positive likelihood ratio was 72 %, 73 %, and 2.72, respectively (Table 2). For calibration, H/L- C statistic was 13.5, p = 0.2. And also, Brier score (95% CI) was 0.16 (0.15, 0.17) (Fig. 4, Table 2).

Conclusions
We developed a simplified THAI-ICU score which outperformed the standard severity score and can be considered as a powerful tool to predict hospital mortality. The simplicity of THAI-ICU score will increase the possibility to feasibly apply in resource limited setting.

Acknowledgment
The study was on behalf and supported by SEA-AKI study group; Dr. Nattachai Srisawat as the research group leader.
References
1. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care. 2004;8(6):508-512. DOI: 10.1186/cc3000. PMC1065080.
2. Labarère J, Bertrand R, Fine MJ. How to derive and validate clinical prediction models for use in intensive care medicine. Intensive care medicine. 2014;40(4):513-527. DOI: 10.1007/s00134-014-3277-6.
3. Granholm A, Perner A, Krar M, Hjortrup PB, Haase N, Holst LB, Marker S, Collet MO, Jensen AK, Møller MH. Development and internal validation of the Simplified Mortality Score for the Intensive Care Unit (SMS-ICU). Acta Anaesthesiologica Scandinavica. 2018; Mar;62(3):336-346.
4. Hanilla R, Mukaka M, Munasinghe SB, De Silva AP, Banner-Goodspeed VM, Weinkauf JL, Talmon D, Tawaniupec T. Predicting mortality in low-income country ICUs: the Rwanda Mortality Probability Model (R-MPM). PLoS one. 2016;19;11(5):e0155858.

Fig. 1 (abstract P5). Flow chart of subject disposition for the THAI-ICU Score study, randomly into development cohort and validation cohort.

Fig. 2 (abstract P5). Forest plot in log-10 scale of odds ratio (adjusted for age, gender, body mass index and comorbidities; including hypertension, diabetes, coronary artery disease, cerebrovascular disease, malignancy, chronic kidney disease) in prediction of non-survivor.

Table 1 (abstract P5). Creating the THAI-ICU score of development cohort with multivariable regression-based method (n=3,458).

| Predictors | 6 variables Model | 8 variables Model | 8 variables Model | 8 variables Model |
|------------|------------------|------------------|------------------|------------------|
| B | Adjusted odds ratio (95% CI) | Score | B | Adjusted odds ratio (95% CI) | Score |
| GCS 10-14 | 1.43 (1.08, 1.90) | 4.0 | 4.08 (3.09, 5.41) | 4.0 |
| < 10 | 2.56 (1.94, 3.40) | 13.0 | 2.48 (1.89, 3.25) | 12.0 |
| MAP > 70 | 0.85 (1.03, 1.62) | 2.5 | 0.81 (1.52, 2.77) | 2.0 |
| Fluid > 1 | 0.26 (1.30, 1.90) | 1.5 | 0.22 (1.02, 2.75) | 1.0 |
| E. coli | 0.65 (1.01, 1.33) | 2.0 | 0.49 (1.74, 2.71) | 2.0 |
| pH < 1 | 0.59 (1.03, 1.84) | 1.5 | 0.47 (1.74, 2.59) | 1.5 |
| TB < 2 | 0.58 (1.03, 1.84) | 2.0 | 0.47 (1.74, 2.71) | 2.0 |
| TB ≤ 29 | 0.58 (1.03, 1.84) | 2.0 | 0.47 (1.74, 2.71) | 2.0 |
| Maximum score | 22.5 | 23.5 |

Fig. 3 (abstract P5). The area under the receiver operating characteristic (ROC) curve for mortality prediction of each model of simplified THAI-ICU scores, comparing with APACHE II and SOFA in validation cohort. AUC: area under ROC curve.

Fig. 4 (abstract P5). Calibration curve comparing between observed and predicted mortality at each cut-point of THAI-ICU score 6 variables in validation cohort.
**P6**

The role of novel immunologic biomarkers in prediction of outcomes in severe sepsis/septic shock patients

Chalermtchai Komaenthammasophon1,2, Nuttha Lumlertgul1,2, Sasipha Tachaboon1,2, Janejira Dinhuzen1,2, Sadudee Peerapornratana1,2, Nattachai Srisawat1,2

1Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok Thailand

**Correspondence:** Nuttha Lumlertgul (nlumlertgul@gmail.com)

*Intensive Care Medicine Experimental 2018, 6(Suppl 1):P6*

**Background**

Innate immune response is an important host response to infection. However, the role of neutrophil chemotaxis activity, CD11b expression on neutrophils, and monocyte HLA-DR (mHLA-DR) expression as novel prognostic biomarkers in patients with severe sepsis/septic shock is still unknown. The purpose of this study was to evaluate the discriminatory characteristics of these biomarkers on mortality.

**Materials and methods**

This prospective cohort study was conducted at intensive care units, King Chulalongkorn Memorial hospital. Patients with severe sepsis or septic shock were enrolled. We collected blood samples at the time of enrollment to test immunologic biomarkers. Neutrophil function was evaluated by measurement of neutrophils chemotaxis activity and CD11b expression. Monocyte function was assessed by the measurement of mHLA-DR expression, a key marker of immunoparasitism, and presepsin level. The primary end point was 28-day mortality.

**Results**

A total of 136 participants were enrolled. Patients were classified by mortality at day 28 into 2 groups as survivors group (n=59, 43%) and non-survivors group (n=77, 57%). Neutrophil chemotaxis activity was significantly higher in survivors group than non-survivors group (46.7% vs. 41.4%, p=0.027). There was significantly lower CD11b expression on neutrophils in survivors than non-survivors (10.3% vs. 14.8%, p=0.012). There were no significant differences in mHLA-DR expression and presepsin level between survivors and non-survivors. Neutrophil chemotaxis activity predicted 28-day mortality with an area under the receiver operating characteristic curve (AUC-ROC) of 0.76 (95% CI 0.67-0.85), while the HLA-DR, CD-11b expression, and presepsin showed the AUC-ROC of 0.69 (0.60-0.79), 0.71 (0.61-0.80), and 0.62 (0.51-0.72), respectively. Neutrophil chemotaxis activity at the cutoff of 49% showed the sensitivity of 0.51, and specificity of 0.71. By stepwise analysis, combining neutrophil chemotaxis activity with mHLA-DR, CD11b expression, presepsin, and SOFA score provided the highest AUC-ROC of 0.84 (0.77-0.91) in predicting 28-day mortality.

**Conclusions**

Neutrophil chemotaxis activity appeared to be a promising novel immunologic biomarker in predicting 28-day mortality in patients with severe sepsis or septic shock.

**Acknowledgements**

The investigator-initiated study was funded by an unrestricted research grant from Ratchadapiseksomphot endowment fund, Faculty of Medicine, Chulalongkorn University. Statistical analysis was conducted by Miss Pimnara Peerawaranun.

**P7**

A case report of *Pasteurella multocida* sepsis incidentally found with multiple myeloma

Takanori Sekito1, Masami Ishikawa2

1Department of General Medicine, Kure Kyosai Hospital, Hiroshima, Japan; 2Department of Emergency and Critical Care Medicine, Kure Kyosai Hospital, Hiroshima, Japan

**Correspondence:** Takanori Sekito (t.sekito41@gmail.com)

*Intensive Care Medicine Experimental 2018, 6(Suppl 1):P7*

**Background**

*Pasteurella multocida* (PM) is a common cause of zoonotic infection following bites or scratches from dogs or cats. However, PM sepsis rarely occurs in healthy adults. We encountered a case of PM sepsis probably due to multiple myeloma (MM).

**Patient**

A 69-year-old female was transported to the emergency room with symptoms relating to polymyalgia and polyarthalgia. On first presentation, she reported no notable past medical history, including MM. Clinical course: She was alert and oriented, with vital signs as follows: blood pressure, 99/59 mmHg; heart rate, 102 bpm; respiratory rate, 34/min; SpO2 92% (room air); and body temperature, 38.9 °C. Hematological investigations indicated anemia, a low platelet and leukocyte count, an elevated D-dimer value and an elevated C-reactive protein level. Based on these results, she was diagnosed with sepsis and disseminated intravascular coagulation (DIC) and admitted into the intensive care unit for general management. Meropenem were initially administrated for sepsis and Danaparoid sodium was administered to treat the DIC. A blood cultivation test grew PM and the antibiotic prescription was tailored to Cefazolin. Electrophoresis was performed and showed IgG κ type M-protein during hospitalization. Because her fever recurred, the antibiotics were tailored to Ceftriaxone. Her vital signs gradually normalized and her general condition, including the polymyalgia and polyarthalgia, gradually improved. On hospital day 29, she had resumed activities of daily living and was discharged, with anemia and M-proteinemia remaining. Post-discharge, bone marrow aspiration was performed at follow-up showing more than 35% of plasma cells and symptomatic MM was diagnosed.

**Discussion and conclusion**

PM is usually carried by cats and dogs. PM infection in humans is often associated with direct animal contact such as an animal bite, scratch, lick, or kiss, and PM is likely to occur in older people and immunocompromised hosts. Our patient had a cat at home but denied any history of a cat bite. She was a compromised host because of the MM which likely led to the PM infection and sepsis. Possible underlying immunocompromised conditions should be considered
when diagnosing PM sepsis, even where patients have no obvious past medical history on initial presentation.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief on request.

P8
Diagnostic and treatment of bone and joint sepsis in newborns
Gennady Khanes1, Tetiana Ivanova1, Olga Lyutko2
1. Ukrainian National Specialized Pediatric Hospital
OkhMatDyt, Kyiv, Ukraine; 2. “Research Institute of Orthopedics of Medical Sciences of Ukraine, Kyiv, Ukraine

Correspondence: Gennady Khanes (dhanes188@gmail.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P8

Background
Bone and joint sepsis (osteomyelitis and arthritis) account for up to 20% of all purulent-septic pathology in newborns. Studies of the last 10 years show that in the development of bone-joint sepsis an important role is played by intranatal and contamination infection, which leads to coagulation disorders. An important role in the development of bone-joint sepsis in infants is played by (physiological) immunodeficiency and, as a consequence, immunity disorders.

Materials and methods
For 10 years (2007-2017), 300 newborns with bone-joint sepsis were treated. The leading role in the diagnosis of bone-joint neonatal sepsis is played by the evaluation of the inflammatory process with the help of general tests of CRP, PCT, a general blood test - % monocytes and coagulation disorders. Locally - an assessment of the inflammatory process with the help of an ultrasound examination and an LE-test. From 12-14 days of the disease, the x-ray examination retains its significance.

Results
In 44.1% of patients we have positive microbiological tests, wherein a variety of isolated Staphylococcus and Streptococcus, which are 100% of the sensitive glycopeptid. MSSA also sensitive to rifampicin, amoksiklav and cefoxitin. Enterococci are sensitive to glycopeptides, lineozid, piperocillin / tazobactam, amoksiklav. The greatest resistance to antibiotics showed Enterococcus faecium and Bacillus spp.

Conclusions
In the success of the treatment of bone-joint sepsis is adequately selected in the first hours of admission antibiotic therapy (the first three hours - a cure of 98%). Staphylococci are the main etiological factor of bone and joint sepsis in young children. To clarify the etiology of the disease serology are important.

P9
Development and validation of nurse-directed weaning protocol in a mixed ICU setting - Theptarin weaning protocol
Plianpan Panitta1, Trakarnvijitr Sirireudee1, Chongartklang Saifon1, Wongasa Patsaraporn1, Ketwaengkuang Puntisa1, Chotjirat Anocha1, Thewjetcharoen Yotsapon1, Himathongkarn Thep2
1. Intensive Care Unit, Theptarin Hospital, Bangkok, Thailand; 2. Department of internal medicine, Theptarin Hospital, Bangkok, Thailand

Correspondence: Plianpan Panitta (kobicu08@gmail.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P9

Background
Prolonged mechanical ventilation of critically ill patients is associated with adverse clinical outcomes. Therefore, mechanical ventilation should be discontinued as soon as patients are capable of breathing independently. Studies have shown that weaning protocols lead to a decrease in duration of mechanical ventilation and complications associated with mechanical ventilation. This study aims to develop and validate a weaning protocol to use in a mixed ICU setting based on 4 components to achieve successful weaning process from the first step of readiness to wean criteria until the final step of structured monitoring after extubation.

Conclusions
Our validated Theptarin weaning protocol could identify patients who were ready to wean from mechanical ventilator in a timely manner and could be applied in a mixed ICU setting with empowerment of ICU nurses. The implementation of this simple nurse protocol into the routine weaning practice and periodic audits should be done to demonstrate outcome benefits for patients.

P10
The levels of plasma Calprotectin and other biomarkers in early sepsis
Aleksandra Havelka1,2, Anders Larsson3, Joachim Johansson4, Jonas Tydén5, Mikiås Lipcsey6
1. Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; 2. Gentian Diagnostics AB, Stockholm, Sweden; 3. Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 4. Department of Anaesthesia and Intensive Care Ostersund, Umeå University, Umeå, Sweden; 5. Department of Surgical Sciences, Anaesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden

Correspondence: Aleksandra Havelka (aleksandra.havelka@gentian.no)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P10

Background
Sepsis is a condition with high mortality where early treatment improves outcome suggesting that rapid identification of patients with sepsis is important. Calprotectin is a novel biomarker that can be analysed in routine laboratory with short turnaround times. We set out to determine the levels of plasma Calprotectin in patients with and without sepsis on intensive care (ICU) admission and as a marker of mortality day 30 post ICU admission.

Materials and methods
All adult patients with arterial cannula that were primarily admitted to the mixed ICU at Östersund General Hospital between the 1st of February 2012 and 31st of January 2013 were screened for discharge diagnoses. Plasma taken on admission from patients was analysed for Calprotectin, and the more investigated sepsis biomarkers Heparin Binding Protein (HPB) and Procalcitonin. We compared levels of these biomarkers in patients with sepsis (defined according to Sepsis 2) with levels in patients admitted for trauma, i.e. controls with inflammation, patients with other medical conditions (OMC), i.e. medical admissions with no infection, and finally with medical and surgical patients presenting without these pre-specified diagnoses (Miscellaneous conditions).
Results
328 patients met the inclusion criteria. 83 patients had sepsis, 33 trauma, 77 OMC as discharge diagnosis and 118 Miscellaneous conditions. Mortality at 30 days was 20% for sepsis patients, 9% for trauma patients, 21% for patients with OMC and 25% for patients with Miscellaneous conditions. The levels of Calprotectin were higher in sepsis vs. trauma patients ($p<0.001$, Fig. 1), sepsis vs. OMC ($p<0.01$), sepsis vs. Miscellaneous conditions ($p<0.01$) and was higher in patients who did not survive to 30 days ($p<0.01$). HPB levels were higher in sepsis vs. trauma patients ($p<0.001$, Fig. 2), sepsis vs. OMC ($p<0.001$), but were comparable sepsis vs. Miscellaneous conditions (n.s.). HBP was higher in patients that were dead at 30 days ($p<0.001$). Plasma Procalcitonin did not differ between the groups or for outcome (Fig. 3).

Conclusions
Calprotectin may be superior to Procalcitonin and HBP in indicating patients with sepsis as Calprotectin, unlike HBP and Procalcitonin, was consistently higher in sepsis patients compared to patients with other diagnoses with and without systemic inflammation. Calprotectin and HBP showed predictive ability regarding 30 days mortality. Procalcitonin did not.

Prognostic value of DNA-traps level in blood smears from patients with sepsis
Darya V Mosalskaya1, Alexander S Guriev1,2, Andrey F Lopatin1
1MF-Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI), scientific-research laboratory, Moscow, Russian Federation; 2Medtechnopark LTD, Moscow, Russian Federation
Correspondence: Andrey F Lopatin (cohemeph@mail.ru)

P11
Prognostic value of DNA-traps level in blood smears from patients with sepsis

Background
In 2004 a novel suicidal antimicrobial strategy of human neutrophils was described, named NETosis (NET – Neutrophil Extracellular Trap) [1]. NETosis is the particular case of ETosis (ET – Extracellular Trap), which is specific for a variety of human phagocytes. During ETosis phagocytes are transformed, resulting in subcellular structures formation, such as so-called extracellular DNA-traps (DTs), consisted of nuclear DNA with immobilized antimicrobial proteins and enzymes. DTs efficiently bind and kill microorganisms, however they are toxic to host cells. DTs play important role in thromboses, inflammatory and autoimmune diseases [2]. DTs are known to be important in the pathogenesis of sepsis [3]. At the same time standard methods for determination of ETosis-transformed phagocytes in human blood are not developed yet [4]. New method [5] was proposed for ETosis-transformed phagocytes determination in blood of patients with sepsis, based on DTs calculation in standardized thin blood smears. However, additional studies are needed to confirm its clinical usefulness. The aim of this study is to evaluate the connection between increased DTs level (in blood smears from patients with sepsis) with outcome of the disease.

Materials and methods
DTs levels were determined in blood smears of 51 patients in intensive care unit with verified sepsis. 55 healthy donors were in control group. Peripheral venous blood was collected into tubes containing EDTA, standardized thin blood smears were prepared using 2 µl of blood, and stained with Giemsa stain. Levels of DTs were calculated using automated microscopy system MECOS-C2 (Moscow, Russia). Blood of the patients was studied several times during staying in intensive care unit; the maximal DTs levels during all time of observation were analyzed.

Results
Among 51 patients with sepsis 20 died and 31 recovered. The most informative indicator was the maximal DTs level during all time of observation. In group of all patients this indicator was in average...
15.1% (σ=14.9%, Min-Max: 1–72%). Died patients – 25.3% (σ=18.9%, Min-Max: 5.6%–72%). Recovered patients – 8.7% (σ=5.3%, Min-Max: 1%–22.5%). Healthy donors – 5.7% (σ=2.5%, Min-Max: 1.8%–11.9%). The differences between the groups were statistically significant according to Mann-Whitney U-test: donors vs septic patients – p=0.000026; recovered vs died patients – p=0.015** (Fig. 1).

Conclusions
In average, maximal DTs level was significantly higher in patients with sepsis than in healthy donors. Besides, maximal DTs level was significantly higher in died patients than in recovered patients. These results allow to conclude, that high level of DTs in patients with sepsis correlates with lethal outcome.

References
1. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 2004, 303(5663):1532-1535.
2. Papayannopoulos V: Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 2018, 18(2):134-147.
3. O’Brien X, Biron B, Rechner J: Consequences of extracellular trap formation in sepsis. Curr Opin Hematol 2017, 24(1):66-71.
4. Masuda S, Nakazawa D, Shida H, Miyoshi A, Kusunoki Y, Tomaru U, Ishizu A: NETosis markers: Quest for specific, objective, and quantitative markers. Clin Chim Acta 2016, 459:89-93.
5. Gur’ev A, Mosalikaya D, Lopatin A, Rusanova E, Vasilenko I, Volkov A. Determination of phagocytes, transformed during etosis, by morphological method in patients with sepsis. High medical technologies in XXI century: materials of the round table 2017, 57.

![Fig. 1 (abstract P11). Maximal DTs levels during all time of observation in blood smears from patients with sepsis and healthy donors](image)

P12
Monitoring the activity of antithrombin in sepsis allows predicting the likelihood of a clinical outcome of the disease
Ivan V Redkin, Andrey F Lopatin, Vera V Samoylenko, Yury V Skripkin, Valery V Likhvantsev
Moscow Regional Scientific Research Clinical Institute, Russia, Moscow
Correspondence: Audrey Lopatin (mdalopatin@hotmail.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P12

Background
Disturbance of hemostasis plays an important and sometimes decisive role in the development of multiple organ failure and the clinical outcome of sepsis. The question - "What diagnostic criterion of hemostasis can be most useful for assessing the dynamics and outcome of sepsis?" - to this day remains open.

Materials and methods
A retrospective, observational, cohort study of the dynamics of inflammatory response and hemostasis in patients with sepsis was performed. 83 patients were included in the study. The diagnosis of sepsis is based on the presence of a foci of infection and SOFA more than 4, confirmed by isolates of pathogens from the blood.

On the outcome of the disease, two groups of patients were formed: 1) - survivors (n = 41), 2) - dead (n = 42). Laboratory data of patients from both groups were retrospectively studied: 1) at the time of diagnosis of sepsis and 2) the 5th day of the disease. The tests included the determination of blood leukocytes, young forms of neutrophils, lymphocytes, total plasma protein and albumin, plasma creatinine, C-reactive protein, procalcitonin (PCT), platelets, fibrinogen concentration, activity of antithrombin, D-dimer level. In dead patients, pathohistological studies were performed to identify microthrombosis of the vascular bed.

Results
At the stage of sepsis diagnosis in the groups of statistically significant differences by the studied parameters was not revealed. An exception was albumin and PCT, the values of which could be taken to predict the likelihood of an adverse outcome. Albumin (Odds ratio - 2.6 [1.0595 - 6.5038], P = 0.0371); PCT (Odds ratio - 9.2500 [2.7763 - 30.8184], P = 0.0003). However, the ROC analysis data do not allow us to substantiate their recommendation for the prognosis of the outcome of the disease. Albumin Cut-off ≤26 g/l, sensitivity/ specificity - 70%/53%; PCT - Cut-off > 16.2 ng/ml: sensitivity/specificity - 48%/90.

After 5 days (stage 2 of the study), the level of activity of antithrombin was significant for the prognosis of the outcome of sepsis (Odds ratio - 26.4 [8.02 - 86.86]); P < 0.0001. ROC analysis of the level of activity of antithrombin as a predictor of lethal outcome revealed a high sensitivity (79%) and specificity (88%) for the value (Cut-off) ≤61%. Data of pathohistological studies of deceased patients revealed microrcirculatory thrombosis of the vascular bed in 73.6%.

Conclusions
The obtained results show that at the stage of development of sepsis there is a high heterogeneity of indices of inflammatory reaction and hemostasis. The revealed regularity of the dynamics activity of antithrombin in patients with sepsis indicates one of the leading pathophysiological links in the multiple organ failure and allows us to recommend an antithrombin activity test for predicting the dynamics and probability of the outcome of the disease.

P13
Open label prospective randomised control study of high cut point level of procalcitonin guided antibiotic therapeutic protocol in surgical critically ill patients
Kaweesak Chittawatanarat, Narain Chotirosniramit, Kamtone Chandacharn, Tidarat Jirapongcharoenlap, Rungrapa Peerakam, Mudjalan Areerug
Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Correspondence: Kaweesak Chittawatanarat (kchittaw@gmail.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P13

Background
Post-operative fever is a common problem. In some situations, it is to distinguish infection from non-infection. Procalcitonin is claimed to be beneficial for identifying infection. However, the cut point value is still not concluded especially on post-operative critically ill patient. To show the benefit of efficacy of procalcitonin in post-operative fever in surgically critical ill patients. The cut point of less than 1 ng/
ml is used for guiding physician to discontinue antibiotic. The mortality rate and reinfection rate were analyzed.

Materials and methods
An open label randomized control study was conducted. One hundred hospitalized patients in surgical intensive care unit, sub surgical intensive care unit and trauma intensive care unit of Maharaja Nakorn Chiang Mai Hospital from July 2016 to January 2017 were eligible in this study. The patients were divided into two groups, usual care group (UC) and procalcitonin-guided treatment group (PC).

Results
One hundred patients were included in the study. Baseline characteristics were not statistical significant different between groups. Mean antibiotic duration and antibiotic free day were statistical significant different between group (PC vs. UC :8.5 days (IQR 5-17) vs. 14 days (IQR 8-28), (p=0.015); and 18 days (IQR 0-23) vs. 7.5 days (IQR 0-17), (p=0.023) respectively). 90-day mortality and recurrent infection were not statistical significant different (90 days mortality (12/50) 24% vs. (11/50) 22%, Hazard ratio, HR, (95% confidence interval) 0.91 (0.41-2.03), p=0.818; hospital recurrent infection (14/50) 28% vs. (21/50) 42%, Hazard ratio, HR, (95% confidence interval) 0.62 (0.31-1.21), p=0.161.

Conclusions
The high cut point of procalcitonin level of 1 ng/ml or below 70% of initial level decrease antibiotic usage duration in post-operative surgical critically ill patients without differences on 90 days mortality and hospital re-infection.

Acknowledgements
Faculty of Medicine, Chiang Mai University.

---

P15

Whether bacteremia is important in the treatment of sepsis?

Julia Fuss¹, Anna Voloboyeva²
¹Department of physical rehabilitation, D.Halycky Lviv National Medical University, Lviv, Ukraine; ²Department of intensive care Central Region Hospital in Pustomty, Pustomty, Ukraine

Correspondence: Julia Fuss (juliafuss78@gmail.com)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P15

Background
Sepsis is a generalized infectious disease, has no propensity to self-destruct [1]. At present, the idea of the importance of bacteremia in sepsis is not systematized. There are data based on the frequency of bacterial isolation from the blood of patients with sepsis, which, depending on the severity of the patients, varies from 20 to 80% [2, 3].

Materials and methods
Diagnosis of 96 cases of sepsis with positive hemoculture in patients was carried out. The study included 58 men and 38 women aged 18 to 78 years. All patients were divided into groups depending on the underlying disease. Blood culture from all patients was carried out on nutrient media. The sensitivity of the isolated pathogens to antibiotics is used for guiding physician to discontinue antibiotic. Antibacterial duration and antibiotic free day were statistical significant different between group (PC vs. UC :8.5 days (IQR 5-17) vs. 14 days (IQR 8-28), (p=0.015); and 18 days (IQR 0-23) vs. 7.5 days (IQR 0-17), (p=0.023) respectively). 90-day mortality and recurrent infection were not statistical significant different (90 days mortality (12/50) 24% vs. (11/50) 22%, Hazard ratio, HR, (95% confidence interval) 0.91 (0.41-2.03), p=0.818; hospital recurrent infection (14/50) 28% vs. (21/50) 42%, Hazard ratio, HR, (95% confidence interval) 0.62 (0.31-1.21), p=0.161.

Conclusions
The high cut point of procalcitonin level of 1 ng/ml or below 70% of initial level decrease antibiotic usage duration in post-operative surgical critically ill patients without differences on 90 days mortality and hospital re-infection.

Acknowledgements
Faculty of Medicine, Chiang Mai University.

---

P14

Whether bacteremia is important in the treatment of sepsis?

Julia Fuss¹, Anna Voloboyeva²
¹Department of physical rehabilitation, D.Halycky Lviv National Medical University, Lviv, Ukraine; ²Department of intensive care Central Region Hospital in Pustomty, Pustomty, Ukraine

Correspondence: Julia Fuss (juliafuss78@gmail.com)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P14

Background
Sepsis is a generalized infectious disease, has no propensity to self-destruct [1]. At present, the idea of the importance of bacteremia in sepsis is not systematized. There are data based on the frequency of bacterial isolation from the blood of patients with sepsis, which, depending on the severity of the patients, varies from 20 to 80% [2, 3].

Materials and methods
Diagnosis of 96 cases of sepsis with positive hemoculture in patients was carried out. The study included 58 men and 38 women aged 18 to 78 years. All patients were divided into groups depending on the underlying disease. Blood culture from all patients was carried out on nutrient media. The sensitivity of the isolated pathogens to antibiotics is used for guiding physician to discontinue antibiotic. Antibacterial duration and antibiotic free day were statistical significant different between group (PC vs. UC :8.5 days (IQR 5-17) vs. 14 days (IQR 8-28), (p=0.015); and 18 days (IQR 0-23) vs. 7.5 days (IQR 0-17), (p=0.023) respectively). 90-day mortality and recurrent infection were not statistical significant different (90 days mortality (12/50) 24% vs. (11/50) 22%, Hazard ratio, HR, (95% confidence interval) 0.91 (0.41-2.03), p=0.818; hospital recurrent infection (14/50) 28% vs. (21/50) 42%, Hazard ratio, HR, (95% confidence interval) 0.62 (0.31-1.21), p=0.161.

Conclusions
The high cut point of procalcitonin level of 1 ng/ml or below 70% of initial level decrease antibiotic usage duration in post-operative surgical critically ill patients without differences on 90 days mortality and hospital re-infection.

Acknowledgements
Faculty of Medicine, Chiang Mai University.

---

P15

Treatment of purulent wounds with VAC-therapy

Anna Voloboyeva¹, Julia Fuss²
¹Department of intensive care Central Region Hospital in Pustomty, Pustomty, Ukraine; ²Department of physical rehabilitation, D.Halycky Lviv National Medical University, Lviv, Ukraine

Correspondence: Julia Fuss (juliafuss78@gmail.com)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P15

Background
In present the problem of treatment purulent-inflammatory diseases and is currently relevant to clinical surgery [1]. Despite significant advances, associated with the expansion deepening of knowledge about etiology, pathogenesis, clinical manifestations of surgical infection based on the modern advances in immunology, microbiology, biochemistry, reduction in number of patients and the severity of purulent surgical diseases is not observed [2]. Proper use of vacuum system can significantly reduce the wound regeneration and the cost of treatment for this category of patients. Vacuum therapy improves the course of all stages of the wound process [3,4].

Materials and methods
The results of treatment of 54 patients with severe surgical soft tissue infection at the age from 18 to 75 years who were treated at the department of purulent surgery were presented. In the treatment of 25 patients, system that created negative pressure was used in the wound in a constant or alternate regimen. The use of vacuum system and therapy with negative pressure was carried out after radical necrectomy. The control group consisted of 29 patients, in which the treatment was not included vacuum therapy. Keeping wounds in the control series was carried out in a semi-open manner using frequent dressings, local application of traditional antiseptics and ointment antibacterial compositions.

Results
In basic group in 19 patients from 25 in wounds identified a number of pathogens and opportunistic microorganisms. The analysis of the results of cytological control in the comparison groups allowed to establish that in the first 3-6 days after the operation, in all types of post-operative wound management, the necrotic type of the cytogram was dominated. The decrease in the level of bacterial invasion of the wound tissues below the critical (103 CFU/g) during NPWT therapy was achieved on average by the 3rd day against 7 days in traditional methods of local wound healing (p <0.05). In all patients, where was used vacuum system, pronounced positive effect of treatment was mostly noted, what optimized the timing of
cleansing and healing of wounds. In the control group until the 15th day of observation, complete closure of the defect was noted only in 3 patients (16.7%).

Conclusions
The usage of wound healing technology by negative pressure promotes mechanical elimination from purulent foci of a large number of microbial bodies and products of tissue decay, which slows healing of the wounds, reduces interstitial edema of tissues, improves their lymph and blood circulation.

References
1. Anagnostakos, K. Bacteria identification on NPWT foams: clinical relevance or contamination / K Anagnostakos, P. Mosser // Wound Care. – 2014. – Vol. 23. – P. 191–194.
2. Orgill, D. P. Negative pressure wound therapy: past, present and future / D. P. Orgill, L. R. Bayer // Int. Wound J. – 2013. – Vol. 10, Suppl 1. – P. 15–9.
3. Schintler, M. V. Negative pressure therapy: theory and practice / M. V. Schintler // Diabetes Metab. Res. Rev. – 2012. – Vol. 28, Suppl. 1. – P. 72–77.
4. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation / M. Morykwas et al. // Ann. Plast. Surg. – 1997. – Vol. 38 (6). – P. 553–562.

P17
Prognostic value of Pentraxin-3, procalcitonin and lactate in patients with sepsis and septic shock in emergency departments
Ju-Hyun Song1, Hyeri Seok2, Won Suk Choi, Sungwoo Moon, Dae Won Park
1Department of Emergency Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea; 2Division of Infectious Diseases, Korea University Ansan Hospital, Ansan, Republic of Korea
Correspondence: Dae Won Park (pugae1@hanmail.net)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P17

Background
Pentraxin-3 (PTX3) is an acute phase protein involved in inflammatory and infectious processes. The purpose of this study was to confirm the prognostic value of PTX3 compared to procalcitonin (PCT) and lactate in patient with sepsis and septic shock.

Materials and methods
A prospective, observational study was performed from December 2017 to May 2018 in a tertiary care hospital. Serum levels of PTX-3, PCT, lactate, and interleukin-6 (IL-6) were measured on admission and around outcome developed day.

Results
The study included 91 patients, 47 (51.6%) of whom were male, 45 (49.5%) of whom developed septic shock, and 35 (38.5%) of whom died in the stay of hospital. The level of PTX3, PCT, lactate and IL-6 at admission were significantly increased in septic shock patients compared to sepsis patients (45.4 ± 58.1 vs 100.7 ± 75.7 ng/ml, p<0.001; 7.1 ± 21.4 vs 18.7 ± 29.4 ng/ml, p=0.040; 2.5 ± 2.6 vs 6.2 ± 3.5 mmol/L, p<0.001; 1000.3 ± 2435.1 vs 2079.7 ± 46581.1 pg/ml, p=0.007, respectively). The AUROC of PTX3, PCT, lactate and IL-6 to predict in hospital mortality were 0.675 (95% confidence interval [CI] 0.54–0.81, p=0.019), 0.594 (95% CI 0.44–0.75, p=0.216), 0.648 (95% CI 0.51–0.79, p=0.047), and 0.723 (95% CI 0.59–0.86, p=0.003), respectively. Serial changes of PTX3 value in the death was significantly increased (85.7 ± 71.6 vs 229.3 ± 260.7 ng/ml, p=0.003).

Conclusions
PTX-3 reveals prognostic value for in hospital mortality compared to PCT and lactate. Serial increase of PCT3 might be poor prognostic marker.

P18
The hemodynamic effects of oXiris hemofilter in septic shock patients requiring renal support: a case series
Nuttha Lumlertgul1, Nattachat Srisawat2,3
1Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Excellence Center of Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 3The Center for Critical Care Nephrology, CRISMA, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Correspondence: Nuttha Lumlertgul (niumlertgul@gmail.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P18

Background
The excessive release of pro-inflammatory and anti-inflammatory cytokines enables the latter to act as mediators for hemodynamic alterations, metabolic acidosis, and multi-organ failure in severe sepsis. Recently, the oXiris® hemofilter that comprises an AN69 core membrane, polyethylenimine, and which is grafted with heparin, has been introduced as a novel hemofilter membrane to mitigate inflammatory response during sepsis-associated acute kidney injury (AKI) that requires renal replacement therapy (RRT).

Materials and methods
In the present case series, we retrospectively evaluated the impact of the oXiris® hemofilter on hemodynamics and clinically relevant
outcome parameters in critically ill patients with septic shock who require continuous RRT and those with at least two organ dysfunctions.

Results
Thirty-five patients were enrolled. There was a nonsignificant trend for improvement of hemodynamic status as shown by increased mean arterial pressure (MAP), decreased norepinephrine dose, inotropic score, and vasopressor dependency index. Blood lactate and base excess also showed significant improvement. OXiris treatment was safe with no device-related adverse events.

Conclusions
Using OXiris hemofilter was feasible, well-tolerated, and should encourage the conduction of randomized controlled trials to evaluate the potential benefits of this therapeutic option.

Acknowledgements
The authors would like to thank all fellows and staff at the Division of Nephrology, Chulalongkorn University and all intensivists who support this research. The authors would also like to thank Miss Dollyapa Punpanich for statistical analysis.

**P19**

**Very high mortality in septic patients with unidentified pathogens and lower respiratory tract infections**

Anders Martinsen¹, Dag Kvaale², Aleksander Rygh Holten²,³

¹Department of Acute Medicine, Oslo University Hospital, Oslo, Norway; ²Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway; ³Department of Microbiology, Oslo University Hospital, Oslo, Norway

Correspondence: Aleksander Rygh Holten (aleksander.holten@gmail.com)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P19

Background
Unidentified pathogen is a common feature in patients with lower respiratory tract infection. Septic patients with unidentified pathogens have a significantly higher mortality rate (52% vs 21%, respectively; p=0.007). Moreover, septic patients with focus in the lower respiratory tract without identified pathogen had a significantly higher mortality rate (79% vs 69%, p=0.007). The overall 30 days mortality for sepsis was 17% for patients with an identified pathogen opposed to 31% for patients without an identified pathogen (p=0.001, see Table 1 below). High rates of lower respiratory tract infection were found among sepsis patients without identified pathogen (p=0.001, see Table 1 below). The overall 30 days mortality for sepsis was 17% for patients with an identified pathogen opposed to 31% for patients without an identified pathogen (p=0.001, see Table 1 below).

Materials and methods
All patients with suspected sepsis, taken care of by the medical emergency team in the Emergency department of a Norwegian secondary and tertiary care hospital, were prospectively included in this study. The patients were re-evaluated for sepsis after the hospitalization, sepsis diagnosed if the patient fulfilled both of the following criteria: I) Probable infection II) New or deteriorated organ dysfunction corresponding to a Sequential Organ Failure Assessment (SOFA) Score ≥2 in organ systems not primarily infected. Respiratory distress in relation to respiratory tract infection was for instance not included in the SOFA-calculation.

Results
A total of 487 patients were included from May 2017 to May 2018. Three patients were excluded due to incomplete registrations. 201 (42%) were assessed to have had true sepsis. A pathogen probably responsible for the septic episode was identified in 146 (73%). The overall 30 days mortality for sepsis was 17%; 12% in patients with an identified pathogen opposed to 31% for patients without an identified pathogen (p=0.001, see Table 1 below). High rates of lower respiratory tract infection were found among sepsis patients without identified pathogen, compared to patients with identified microbe (56% vs 29%, p<0.001). Moreover, septic patients with focus in the lower respiratory tract without identified pathogen had a significantly higher mortality rate (52% vs 21%, respectively; p=0.007).

Conclusion
Unidentified pathogen is a common feature in patients with lower respiratory tract infections and in our cohort also associated with very high mortality. Efforts should be made to improve early identification of pathogens in such patients.

### Table 1 (abstract P19). See text for description

|                     | Sepsis with identified pathogen | Sepsis without identified pathogen | p-value |
|---------------------|---------------------------------|------------------------------------|---------|
| Patients            | 146                             | 55                                 |         |
| Median age (first - third quartile) | 73 (58 - 82)                    | 79 (69 - 85)                      | 0.027   |
| Dead within 30 days (%) | 17 (12%)                       | 17 (31%)                           | 0.001   |
| Lower respiratory tract sepsis (%) | 42 (29%)                      | 31 (56%)                           | <0.001  |
| Dead within 30 days with lower respiratory tract sepsis (%) | 9 (21%)                      | 16 (52%)                           | 0.007   |
| Urinary tract sepsis (%) | 52 (36%)                      | 5 (9%)                             | <0.001  |
| Positive blood culture (%) | 79 (54%)                   | 0 (0%)                             | <0.001  |

**P20**

**Clinical characteristics and outcomes of patients with Leptospirosis Infection admitted to the Medical Intensive Care Unit: results from the 10-years retrospectively review from the university hospital from the South of Thailand**

Atta Ajinmanurungsi, Rungsun Bhurayantontchai

Division of Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

Correspondence: Rungsun Bhurayantontchai (rungsun2346@gmail.com)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P20

**Background**
Leptospirosis is the zoonotic infection, which is commonly found in all parts of Thailand. The severe form of this infection, as known as Weil’s syndrome, causes multiple organs dysfunction, such as liver failure, renal failure and respiratory failure. The severe Leptospirosis may lead to morbidity and mortality after intensive care unit admission. We, hereby, presented the clinical characteristic and outcomes of severe Leptospirosis patients, who were admitted to the medical intensive care unit (MICU) in the university hospital from the South of Thailand.

**Materials and Methods**
The retrospectively chart review of the patients who were admitted to MICU with leptospirosis was done. Leptospirosis infection was confirmed by the positive microcapsule agglutination test for leptospira antibody from either the first or the second titer. Patients were then dichotomized into ICU-survivor and non-ICU-survivor group. All clinical characteristics included demographic data, clinical presentation and laboratory tests were recorded and compared by either Chi square test or independent t-test as appropriated. P-value < 0.05 was defined as statistically significant.

**Results**
Of 27 confirmation cases of severe leptospirosis, 77.8% was male with the mean age of 44.6+/-17.4 years old. 55.6% had history of water submersion. The median of presenting symptoms was 3(1,8) days. Fever (100%), myalgia (63%), vomiting (33.3%) and dyspnea (33.3%) were among the common clinical presentation. Mean creatinine level, mean bilirubin level and mean acute lung injury index (ALI) were 4.31+/-2.94 mg/dl, 5.51+/-4.92 mg/dl and 264.3+/-132.6, respectively. In addition, 81.5%, 77.8% and 25.9% of cases required continuous RRT and those with at least two organ dysfunctions.

**Conclusions**
The comparison of survivor and non-survivor was shown in Table 1. Other parameters were comparable between groups. The comparison of survivor and non-survivor was shown in Table 1.
Leptospirosis is the lethal tropical infectious disease, which shown significant mortality in severe cases. Hemodynamic instability, acute kidney injury, acute liver injury and acute respiratory failure were among the common presentation required ICU admission. Female, acidemia, lung injury and coma were related to ICU mortality in this cohort.

**P21**

**Restricted Fluid Resuscitation in Sepsis associated Hypotension (REFRESH): a prospective, multicentre, clinical feasibility trial**

Stephen PJ Macdonald1,2, Gerben Keijzers4,5,6, David M Taylor7, Frances Kinne8,9, Glenn Arendts1,2,25, Daniel M Fatovich1,2,25, Rinaldo Bellomo1,2, David McCutcheon1,2,3,11, John F Fraser2, Juan-Carlos Ascencio-Lane13, Sally Burrows9, Amanda Harley9, Matthew Anstey9,14, Ashes Mukherjee11, Centre for Clinical Research in Emergency Medicine, Perkins Institute of Medical Research, Perth, Australia; 2Medical School, University of Western Australia, Perth, Australia; 3Emergency Department, Royal Perth Hospital, Perth, Australia; 4Emergency Department, Gold Coast University Hospital, Gold Coast, Australia; 5School of Medicine, Bond University, Gold Coast, Australia; 6School of Medical Sciences, Griffith University, Gold Coast, Australia; 7Emergency Department, Austin Hospital, Melbourne, Australia; 8Emergency Department, Prince Charles Hospital, Brisbane, Australia; 9Emergency Department, Fiona Stanley Hospital, Perth, Australia; 10Department of Intensive Care, Austin Hospital, Melbourne, Australia; 11Emergency Department, Armadale-Kelmscott Memorial Hospital, Perth, Australia; 12Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia; 13Emergency Department, Royal Hobart Hospital, Hobart, Australia; 14Department of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia

**Correspondence:** Stephen PJ Macdonald (stephen.macdonald@uwa.edu.au)

**Intensive Care Medicine Experimental 2018, 6(Suppl 1):P21**

**Background**

Surviving Sepsis Campaign guidelines recommend resuscitation with at least 30ml/kg intravenous (IV) fluid in patients with sepsis and hypoperfusion [1]. Trials in developing countries have found higher mortality with larger resuscitation fluid volumes [2, 3]. A clinical trial of a smaller volume of fluid with earlier commencement of vasopressors is warranted, but it is unknown if this intervention is feasible and clinically acceptable in industrialised countries.

**Materials and methods**

The **Restricted Fluid Resuscitation in Sepsis-associated Hypotension (REFRESH)** trial (ACTRN126160000006448), a prospective, randomised, open-label, clinical feasibility trial was conducted in the emergency department (ED) of eight Australian hospitals between October 2016 and March 2018. The protocol has previously been published [4]. Inclusion criteria were suspected infection and hypotension (systolic blood pressure <100mmHg despite at least 1000ml IV fluid). Details of the trial intervention are summarised in Fig. 1. The primary outcome was total fluid administered within the first six hours from presentation. A range of process-of-care, feasibility and clinical outcomes were assessed including vasopressor requirement, protocol adherence, organ failure, and mortality at 90 days post randomisation.

**Results**

There were 99 participants (49 standard and 50 restricted volume) in the intention-to-treat analysis (Fig. 2). Baseline participant characteristics are shown in Table 1. Fluid volume (total for 24 hours from randomisation) and vasopressor use are summarised in Table 2. A significantly lower volume was administered over the first six hours in the restricted volume group (median 30ml/kg vs 43ml/kg, p=0.001) along with earlier commencement of vasopressors (median 1h vs 2h post randomisation, p=0.001). There was no significant difference in the rate of ICU admission, ventilation and acute kidney injury (including dialysis) between the groups. At 90 day follow up 3 of 47 (6%) in the standard arm and 4 of 48 (8%) in the restricted arm had died (P=1.0).

**Conclusions**

A restricted fluid and early vasopressor regimen among ED patients with suspected sepsis and hypotension led to a significant reduction in fluid volume given over the first 6 hours and at 24 hours. Median dose and duration of vasopressors were lower in the restricted volume group, but this was not statistically significant. There were no differences in clinical outcomes, however the study was not designed to detect these. The results demonstrate the feasibility and clinical acceptability of the trial intervention in the Australian ED setting. A large randomised trial to assess the effect on clinical outcomes should be pursued.

**Acknowledgements**

On behalf of the REFRESH Investigators. The trial was part-funded by the Emergency Medicine Foundation (Queensland).

**References**

1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. 2016. Intensive Care Med 2017, 43:304-377
2. Maitland K, Kiguli S, Opoka RO, Engorou C, Olupot-olupot P, Akech SO, Nyoke R, Mtove G, Reyburn H, Lang T, et al. On behalf of the FEAST trial group. Mortality after fluid Olson in African children with severe infection. N Engl J Med 2011, 364:2483-2495
3. Andrews B, Semler MW, Muchemwa L, Kelly P, Lakhi S, Heimburger DC, Mabula C, Bwalya M, Bernard GR. Effect of an Early Resuscitation Protocol on In-Hospital Mortality Among Adults With Sepsis and Hypotension. JAMA 2017, 318:1233-1240
4. Macdonald SP, Taylor DM, Keijzers G, Arendts G, Fatovich DM, Kinne FB, Brown SGA, Bellomo R, Burrows S, Fraser JF, et al. Restricted Fluid Resuscitation in Sepsis-associated Hypotension (RE-FRESH): study protocol for a pilot randomised controlled trial. Trials 2017,18:399

![Fig. 1 (abstract P21). Summary of trial interventions](image-url)
Practice of hemosorption with CytoSorb adsorber for sepsis in cancer patients

Natalia Dmytrievna Ushakova (ndu2000@rambler.ru)

Department of Anesthesiology and Reanimation, Rostov Scientific Research Oncology Institute of the Ministry of Health of Russia, Rostov-on-Don, Russia

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P22

Table 1 (abstract P21). Participant characteristics at baseline. Values are median (interquartile range) unless otherwise stated. SBP – systolic blood pressure; APACHE – Acute Physiology and Chronic Health Evaluation; SOFA – Sequential Organ Failure Assessment

|                      | Standard volume N=49 | Restricted volume N=50 |
|----------------------|----------------------|------------------------|
| Age                  | 66 (45, 76)          | 66 (52, 78)            |
| Male Sex n (%)       | 30 (61)              | 31 (62)                |
| Weight (kg)          | 72 (64, 90)          | 80 (66, 88)            |
| SBP at randomisation | 89 (84, 92)          | 88 (79, 91)            |
| Lactate              | 1.8 (1.2, 2.6)       | 1.7 (1.1, 3.5)         |
| Charlson score       | 2 (0, 4)             | 2 (1, 4)               |
| APACHE II score      | 14 (10, 18)          | 15 (10, 20)            |
| SOFA score           | 5 (4, 7)             | 5 (3, 10)              |
| Non-CVS SOFA score   | 3 (2, 4)             | 3 (1, 6)               |
| Creatinine (μmol/L)  | 130 (80, 170)        | 106 (75, 160)          |
| Acute Kidney Injury N (%) | 30 (60)       | 26 (52)                |
| Sepsis Source N (%)  |                      |                        |
| Respiratory          | 20 (41)              | 14 (28)                |
| Urinary              | 9 (18)               | 16 (32)                |
| Skin/soft tissue     | 6 (12)               | 6 (12)                 |
| Bloodstream          | 7 (14)               | 3 (6)                  |
| Abdominal/pelvis     | 2 (5)                | 5 (10)                 |
| Other/unidentified   | 5 (10)               | 6 (12)                 |

Table 2 (abstract P21). Fluid and vasopressor use. Values are median (interquartile range) unless otherwise stated. T0 - randomisation; T6 – 6 hours post-randomisation; T24 – 24h post-randomisation

|                      | Standard volume | Restricted volume | P value |
|----------------------|-----------------|-------------------|---------|
| Fluid Volume         |                 |                   |         |
| Pre-randomisation    | 1250 (1000, 2000)| 1450 (1000, 1500) | 0.69    |
| T0-T6 (ml)           | 1655 (1017, 2500)| 1273 (792, 1458)  | <0.001  |
| T0-T6/kg (ml)        | 23 (15, 33)     | 12 (7, 20)        | <0.001  |
| Total prerandomisation-T6 | 3000 (2550, 3900) | 2387 (1860, 2750) | <0.001  |
| Total to T6/kg (ml)  | 43 (35, 49)     | 30 (23, 39)       | <0.001  |
| T6-T24 (ml)          | 1000 (428, 1743) | 1134 (500, 2000)  | 0.73    |
| Total prerand-T24 (ml) | 4250 (3500, 5207) | 3543 (2812, 4410) | 0.005   |
| Total to T24/kg (ml) | 61 (46, 79)     | 40 (33, 64)       | 0.005   |
| Vasopressor use N (%)|                 |                   |         |
|                   | 26 (53)          | 39 (78)            |         |
| Vasopressor in ED N (%) | 23 (47)        | 36 (72)            | 0.011   |
| Vasopressor at 24h N (%) | 19 (39)       | 24 (48)            | 0.35    |
| Time to vasopressor commencement from T0 (h) | 2 (1, 3) | 1 (1, 1) | 0.001   |

Type of vasopressor

|                      | Standard volume | Restricted volume | P value |
|----------------------|-----------------|-------------------|---------|
| Noradrenaline N (%)  | 23 (47)         | 30 (60)           | 0.33    |
| Metaraminol only N (%) | 3 (2)          | 9 (18)            |         |
| Central venous access N (%) | 20 (41)   | 26 (52)           | 0.42    |
| Volume prior to vasopressor commencement (ml) | 2000 (2000, 2777) | 1400 (1000, 1700) | <0.001  |
| Duration of vasopressor (h) | 33 (15, 50)   | 21 (9, 42)        | 0.13    |
| Peak vasopressor dose (noradrenaline equivalent) (mcg/kg/min) | 0.18 (0.1, 0.43) | 0.11 (0.08, 0.22) | 0.14    |
| Mean arterial pressure T0-T6 (mmHg) | 72±6        | 73±6              | 0.31    |

**P22 Practice of hemosorption with CytoSorb adsorber for sepsis in cancer patients**

Natalia Dmytrievna Ushakova (ndu2000@rambler.ru)

Department of Anesthesiology and Reanimation, Rostov Scientific Research Oncology Institute of the Ministry of Health of Russia, Rostov-on-Don, Russia

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P22

Background

Numerous studies in the animal experiment, as well as preliminary data on treatment of septic patients have demonstrated that a decrease in cytokine levels in blood can effectively reduce the inflammatory response in sepsis and possibly improve clinical outcome. The aim of the study was to evaluate the effect of hemosorption...
using the CytoSorb column on the course of generalized inflammation in cancer patients.

Materials and methods

11 patients with sepsis were examined. All patients gave voluntary informed consent for the research and publication of the results. Microbiological identification was obtained in 7 cases. The severity of the initial condition on the APACHE-II scale was 24.2 ± 3.3 points, SOFA – 9.2 ± 2.3 points. Organ abnormalities requiring organ-replacement treatment were not recorded. Blood PCT was > 2 ng/ml, EAA did not exceed 0.5. In all cases, hemoresorption using the CytoSorb column was included in the treatment package. Indications for its use was IL-6 blood concentration of more than 800 pg/ml, as an indicator of the severity of hypercytokinemia, which, as previously identified, correlated with a high risk of generalized inflammation progression and MOF. Hemoresorption was performed by the Multifiltrate machine (Fresenius Medical Care, Germany) for a period of 12 – 24 hours. Vascular access was v.subclavia/v.femoralis. Perfusion rate was 150 ml/min. Heparinization was performed using unfractionated heparin. PCT, CRP, IL-6, IL-10 in blood serum were studied. Measurements were taken before hemoresorption, 1 and 6 hours after its completion. The statistical processing of the results was performed using “Statistica 6.0” program with the calculation of the Student’s reliability criterion (t). The difference was considered significant for p<0.05.

Results

After hemoresorption using the CytoSorb column, in 8 out of 11 cases the regress of generalized inflammation activity was noted. PCT reduction was recorded from 27.3 ± 6.7 ng/ml to 4.3 ± 1.1 ng/ml; CRP - from 467.2 ± 98.6 mg/ml to 105.1 ± 54.3 mg/ml; IL-6 - from 1461.3 ± 102.3 pg/ml to 346.5 ± 91.1 pg/ml; IL-10 - from 46.1 ± 4.3 pg/ml to 2.1 ± 0.4 pg/ml; blood lactate - from 5.9 ± 1.7 mg/ml to 1.9 ± 1.2 mg/ml (p<0.05). The SOFA index in these patients decreased by 4.1 ± 1.2 points (p<0.05). In 3 patients inflammatory reaction activity and organ disorders progression was diagnosed, which required the use of other extracorporeal detoxification methods.

Conclusions

Extracorporeal removal of excessively produced inflammatory mediators is an effective and safe auxiliary "tool" in the treatment of sepsis in cancer patients. However, in order to determine the criteria for indications, timing and tactics of combined use with other methods of extracorporeal detoxification, further in-depth studies are needed.

P23

Simple Clinical Score: Predicts mortality in sepsis to early warning score of the emergency room

Manaporn Chatchumni1, Sangrawee Maneesri1, Prapun Singto2, Karn Yongsiwiw2
1School of Nursing, Rangsit University, Pathum Thani, Thailand; 2Department of Medical, Singburi Hospital, Sing Buri, Thailand; 3College of Digital Innovation and Information Technology, Rangsit University, Pathum Thani, Thailand

Correspondence: Manaporn Chatchumni (manaporn@rsu.ac.th)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P23

Background

Raising mortality rate of septic patients has been brought to the emergency room and transfer admission to a medical department. Acute Physiology and Chronic Health Evaluation (APACHE), Simplified Acute Physiology Score (SAPS II) and Simple Clinical Score (SCS) have been used to assess both of acutely and critically ill in the intensive care units and an acute medical unit(1, 2, 3). A limited of tools has been used to assess the early warning score in the emergency room.

Materials and methods

A retrospective case was used designed to describe SCS(2,3) predictive abilities of mortality rate in the patient with sepsis and to compare variables of SCS predictive abilities of different parameters (a status without coma, intoxication or overdose, and aged ≥50 years, new stroke on presentation including age, systolic blood pressure (mmHg), pulse rate > systolic blood pressure, temperature, respiratory rate (per min), oxygen saturation, breathlessness on presentation, abnormal ECG, diabetes (type I or II), coma without intoxication or overdose, altered mental status, unable to stand unaided, or a nursing home resident, prior to current illness, spent some part of daytime in bed. Those lead to mortality. A retrospective analysis of the patient chart record data from all patients diagnosed such as sepsis, severe sepsis or septic shock admitted to the emergency room from December 2016 - November 2017. Local Hospital Research Ethics Committee approval was obtained under code: 0032.2052/80/.

Results

Based on the dataset of 225 patients obtained from the emergency room, we discover that 133 (59.1%) patients are dead, 85 (37.8%) are discharged and 7 (3.1%) are transferred to another hospital as shown in Fig. 1. To describe SCS predictive abilities of mortality rate in the patient with sepsis. Firstly, we use the predictive SCS model to compute the level of SCS for all patients divided by their status after the admission. The results can be summarized in Table 1.

Therefore, the mortality rate for each level of SCS are computed and described in Table 2. The results show that the patients with high and very high level of SCS are dead at the percentage of 26 and 74, respectively.

The second objective is to compare variables of SCS predictive abilities of different parameters lead to mortality. Firstly, we separate our dataset to trained and test data. The trained data consists of 75% of the dataset (167 patient records) and the test data consist of 25% of the dataset (58 patient records). We create a logistic regression model from trained data using the patient’s status ‘dead’ as outcome, with all the variables as independent predictors. From the created model, Table 3 show the important variables for predicting deadly outcome. Oxygen saturation, prior to current illness, spent some part of daytime in bed, coma without intoxication or overdose, respiratory rate (per min) and abnormal ECG are the most important variable for predicting deadly outcome, respectively. We measure the performance of our model using the sensitivity and specificity analysis that are shown sensitivity of 86.7% and specificity of 92.9% for SCS predicts mortality.

We test our model by prediction and comparing with the train data. The result is plotted as the Receiver Operator Characteristic (ROC) curve in Fig. 2. We also calculate the Area Under the Curve (AUC) as AUC = 0.6954657 meaning that the prediction accuracy is quite poor which could be due to the limitation of our dataset.

Conclusions

SCS are not sufficiently accurate to predict mortality in patients with sepsis, which is quite poor quality. However, the outcomes of this analysis known the important variable identification tool for deteriorating patients to early warning sign for detection and prevent adverse events in the patient with sepsis.
References
1. Hamilton F, Arnold D, Baird A, Albur M, Whiting P: Early Warning Scores do not accurately predict mortality in sepsis: a meta-analysis and systematic review of the literature. Journal of Infection 2018, 76(3):241-8.
2. Kellett J, Deane B: The Simple Clinical Score predicts mortality for 30 days after admission to an acute medical unit. Journal of the Association of Physicians. 2006,99(11):771-81.
3. Hamilton F, Arnold D, Baird A, Albur M, Whiting P: Early warning scores do not accurately predict mortality in sepsis: a meta-analysis and systematic review of the literature. Journal of Infection. 2018, 11.

Table 2 (abstract P23). The mortality rate for each level of SCS

| Level of SCS | Mortality rate |
|--------------|----------------|
| Very low     | 0.0            |
| Low          | 0.0            |
| Average      | 0.0            |
| High         | 25.7           |
| Very high    | 73.8           |

Table 3 (abstract P23). The variable importance for logistic regression model

| Variable                                         | Estimate | Std. Error | z value | Pr(>|z|) | Importance |
|-------------------------------------------------|----------|------------|---------|----------|------------|
| Oxygen saturation                               |          |            |         |          |            |
| ≥95%                                            | 1.573306 | 0.4167     | 3.775611| 0.00016  | 3.775611   |
| ≥90% and <95%                                    |          |            |         |          |            |
| <90%                                            |          |            |         |          |            |
| Prior to current illness, spent some part of daytime in bed | 0.87259  | 0.29709    | 2.937088| 0.00331  | 2.937088   |
| Coma without intoxication or overdose            | 0.45074  | 0.16175    | 2.78673 | 0.00532  | 2.78673    |
| Respiratory rate (per min)                       |          |            |         |          |            |
| ≤20                                             | 1.14178  | 0.44229    | 2.581525| 0.00984  | 2.581525   |
| >20 and ≤30                                     |          |            |         |          |            |
| >30                                             |          |            |         |          |            |
| Abnormal ECG                                     | 0.575612 | 0.32636    | 1.76347 | 0.07778  | 1.76347    |
| Pulse rate-systolic blood pressure               | 0.374006 | 0.27959    | 1.33763 | 0.181    | 1.33763    |
| Diabetes (type I or II)                          | 0.511602 | 0.41016    | 1.24733 | 0.21228  | 1.24733    |
| Altered mental status                            | 0.281089 | 0.30121    | 0.933204| 0.35071  | 0.933204   |
| Breathless on presentation                       |          |            |         |          |            |
| Systolic blood pressure (mmHg)                   |          |            |         |          |            |
| >100                                             | 0.218143 | 0.24314    | 0.897179| 0.36962  | 0.897179   |
| >80 and ≤100                                     |          |            |         |          |            |
| ≥70 and ≤80                                     |          |            |         |          |            |
| <70                                              |          |            |         |          |            |
| Age (years)                                      |          |            |         |          |            |
| <50 for men or <55 for women                     |          |            |         |          |            |
| ≥50 for men and ≥55 for women but ≤75 for either|          |            |         |          |            |
| >75 for both men and women                       |          |            |         |          |            |
| Temperature <35 °C or ≥39 °C                     |          |            |         |          |            |
| Unable to stand unaided, or a nursing home resident | 9.354837 | 811.949    | 0.011521| 0.99081  | 0.011521   |
| New stroke on presentation                       | 5.68584  | 1066.55    | 0.005331| 0.99575  | 0.005331   |

Table 1 (abstract P23). The level of SCS for all patients

| Level of SCS | Dead | Discharge | Transfer |
|--------------|------|-----------|----------|
| Very low     | 0    | 3         | 0        |
| Low          | 0    | 7         | 0        |
| Average      | 0    | 9         | 0        |
| High         | 9    | 26        | 0        |
| Very high    | 124  | 40        | 4        |

Fig. 1 (abstract P23). The status of SEPSIS patients after admitted to the emergency room

Fig. 2 (abstract P23). The ROC curve
The efficiency of the Holographic glasses (HoloLens) with Holographic technology consulting application (Nu-med Consult application) that designed and developed to use for the consulting system was used in this study. This study explored the use of the HoloLens by intensivists to provide advice to non-ICU physicians and medical personnel in the ICU.

Materials and methods

A Microsoft HoloLens with Hologram technology consulting application (Nu-med Consult application) that designed and developed to use for the consulting system was used in this study. This study operated in 4 ICUs (1 case-mix ICU, 1 Surgical ICU, 1 Cardiovascular Thoracic Surgical ICU and 1 Trauma ICU) in one tertiary care hospital and one private hospital during 11 April – 11 May 2018. The main purpose of this study was to evaluate the efficiency of the HoloLens for the consulting system in the ICU.

Results

There are totally 17 patients that admitted in ICU were consulted through HoloLens in the period of this study. The topics of consultation were problems in ventilator settings (9 patients), change of symptoms and laboratory results notification (7 patients) and making a decision for ventilator support (1 patient). The questionnaire was used to evaluate the satisfaction of hologram technology in 3 aspects (the system, the utility and the development team) by 1 CVT physician, 1 intensivist and 14 ICU nurses who used HoloLens for the consulting system in the ICU. The mean (SD) of the satisfaction of hologram technology in 3 aspects were 4.37 (0.62), 4.50 (0.63) and 3.87 (0.50) respectively (score out of 5). When mean (SD) of the satisfaction of hologram technology in 3 aspects were allowed detection of 33/34 sepsis patients versus 6/61 controls (Sensitivity 97%, Specificity 90%). Conversely, in sepsis patients, the Leuko64 kit (flow cytometry) was positive in 26/34 (76%) patients, suggesting that the expected upregulation of neutrophil-CD64 during sepsis includes intracellular CD64 that is detected by ELISA but not by the Leuko64 staining method. PCT ECLA detected 24/30 sepsis patients (80%; 95% CI 62.3 to 90.9%).

Conclusion

Measurement of both total CD64, i.e. both surface and intracellular levels of CD64, and NE levels in whole blood appears to be a strong candidate biomarker for diagnosis of sepsis. Further studies in larger cohorts of patients and controls are planned, along with the development of a point-of-care version of the test using methods we have previously used for CD4 T-cells (Visitect® CD4, Omega Diagnostics).
Fig. 1 (abstract P25). CD64 and NE ELISA for whole blood from patients with suspected sepsis (n=34, red squares) or ICU controls (n=9, green triangles) or healthy (n=51), blue circles). (A) Assigned cut-off for total CD64 (1.5 x Mean); 31/34 sepsis patients have levels of CD64 above these cut-offs. Arrows: These eight patients negative by Leuko64™ flow cytometric assay were positive for Total CD64. (B) Expanded data for samples with levels of total NE <2.5 μg/ml, including the 2 neutropenic sepsis samples (red) that have elevated levels of CD64 compared to an assigned cut-off of 1.6 x the trendline for healthy controls.

P26
Rapid identification of pathogens from whole blood clinical samples in critically septic patients by technology of Magnetic Resonance
Cinzia Peronace, Angela Quirino, Aida Giancotti, Giorgio Settimo Barreca, Luisa Galati, Elena Colosimo, Valentina Tancrè, Giovanni Matera, Maria Carla Liberto, Alfredo Focà
Institute of Microbiology, Department of Health Sciences, “Magna Graecia” University, Catanzaro, Italy
Correspondence: C. Peronace (cinziaperonace@hotmail.it)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P26

Background
Rapid and accurate profiling of infection-causing pathogens is crucial for critically septic patient management. During our previous investigations, we evaluated both the performance of some syndromic tests [1,2] and the most successful sepsis biomarkers [3]. Despite advances in molecular diagnostic techniques, blood culture analysis remains the gold standard for diagnosing sepsis. A rapid molecular non-cultural method was recently developed for identification of Candida and bacterial bloodstream infections from whole blood samples. The aim of this study was to evaluate the performance of an automated assay that utilize proprietary T2 Magnetic Resonance technology to enable faster and potentially accurate identification for pathogens that cause sepsis directly from whole blood clinical samples.

Materials and methods
Thirty-six whole blood samples, obtained from critical patients admitted to “Magna Graecia” Hospital of Catanzaro (Italy), were analyzed by innovative technology of Magnetic Resonance (T2 Biosystems, Inc., USA) and compared to a conventional laboratory method (Vitek2, bioMérieux, France). T2MR combines the nuclear magnetic resonance and PCR molecular assay to directly detect six bacteria species (Enterococcus faecium, S. aureus, A. baumannii, E. coli, P. aeruginosa and K. pneumoniae) and the five most common Candida species (C. albicans, C. tropicalis, C. glabrata, C. parapsilosis, C. krusei) directly from freshly obtained whole blood samples, in approximately 3.5-5 h. Specifically, T2 system lyses red blood cells, concentrates microbial cells and cellular debris by mechanical bead-beating, amplifies the DNA using a thermostable polymerase and target-specific primers. The amplified DNA is detected by hybridization to the superparamagnetic nanoparticles, which causes large changes in the sample’s T2MR signal. A synthetic heterologous DNA target used as an internal control, is processed with each clinical specimen, to monitor the integrity of the T2MR results. The limit of detection of T2MR is 1 colony-forming unit (CFU)/mL.

Results
Of the overall 36 whole blood samples tested for candida and bacterial panels, four specimens were not included in the analysis because the internal control was invalid, as well as the samples whose blood cultures were missing (seven specimens). Data obtained by T2MR was confirmed in 100% (11/11) cases for T2Candida panel when compared to Vitek2 method as well as antigen mannann. Concerning T2Bacteria panel, the assay was able to identify 12/14 (86%) specimens when compared to conventional laboratory method respectively. Furthermore, in one case, the novel T2MR assay was capable to detect A. baumannii species after 3.5 h, while the positivity of the conventional blood culture was obtained only six days before.

Conclusions
The data of this study demonstrated that T2MR represents a highly promising molecular diagnostic method for the rapid identification of the most important pathogens causing-sepsis. The use of such technology may warrant a place in the diagnostic pathway of septic syndrome.

Acknowledgements
Authors wish to thank Diagnostic International Distribution (DID, Italy) for the kindly provided T2MR reagents.

References
1. C. Peronace, G. Matera, R. Puccio, V. Marano, G.S. Barreca, A.G. Lamberti, A. Giancotti, A. Quirino, M.C. Liberto, A. Focà Evaluation of a multiplex PCR assay for the rapid identification of bacteria and yeasts in positive blood cultures, EECMID 2014
2. A. Focà, C. Peronace, A. Quirino, L. Galati, G.S. Barreca, L. Gallo, P. Morelli, G. Cortese, M.C. Reale, P. Settembre, I. Addolorato,G. Matera, M.C. Liberto, P. Minchella Evaluation of an automated microscopy-based multiplex FISH assay for bacteria and yeasts identification in positive blood cultures Intensive Care Medicine Experimental 2017, 5(Suppl 1):P41
3. Matera G, Quirino A, Peronace C, Settembre P, Marano V, Loria MT, Marasco N, Galati L, Barreca GS, Giancotti A, Amantea B, Liberto MC, Focà A. Soluble CD14 Subtype-A New Biomarker in Predicting the Outcome of Critically Ill Septic Patients. Am J Med Sci. 2017, 353(6):543-551

P27
Intriguing behavior of cytokines and specific markers in sepsis and septic shock
Cinzia Peronace, Giovanni Matera, Luisa Galati, Aida Giancotti, Angela Quirino, Concetta Zangari, Orietta Eramo, Maria Carla Liberto, Alfredo Focà
Institute of Microbiology, Department of Health Sciences, “Magna Graecia” University, Catanzaro, Italy
Correspondence: C. Peronace (cinziaperonace@hotmail.it)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P27

Background
Our previous studies dealing with pathophysiology of sepsis stressed the main diagnostic role of procalcitonin (PCT) and the major prognostic role of soluble CD14-subtype (presepsin) [1,2]. The aim of the
The present investigation was the assessment of the potential prognostic role of the principal cytokines of Th1, Th2 and Treg cascades.

Materials and methods
In this observational study, we consecutively enrolled critical patients admitted to the Unit of Intensive Care (ICU) of the University Hospital of Catanzaro, Italy. For such patients admission SOFA scores were calculated. Based on 28 days survival subjects were stratified in survivors and nonsurvivors, while a group of healthy volunteers were also included as negative controls. All enrolled patients were subjected to blood cultures. Serum samples were tested for presepsin (PATHFAST Presepsin assay) and procalcitonin (VIDAS B.R.A.H.M.S PCT, bioMerieux, Italy). For all such patients, cytokines levels were evaluated by biochip immunoassay with high sensitivity panel (Randox) at the time of hospital admission. Data were subjected to statistical analysis by ANOVA plus post-hoc PLSD Fisher’s test.

Results
Our data confirmed that presepsin is a valuable prognostic biomarker for the studied patients (p<0.0169). However, PCT did not behave as an affordable prognostic marker. The Treg cytokine, IL-10 seemed to exhibit a trend toward increased values in dead vs. alive patients. Th1 cytokines did not show any significant difference between dead and alive patients at admission time. The Th2 cytokine, IL-4 followed the expected behavior of a lack of any significance in such very early sepsis phase.

Conclusions
In conclusion lack of significance between different groups of cytokines evaluated, further support the value of presepsin as an excellent prognostic biomarker. Although a trend toward significancy was observed for the studied patients (p=0.0169). However, PCT did not behave as an affordable prognostic marker. The Treg cytokine, IL-10 seemed to exhibit a trend toward increased values in dead vs. alive patients. Th1 cytokines did not show any significant difference between dead and alive patients at admission time. The Th2 cytokine, IL-4 followed the expected behavior of a lack of any significance in such very early sepsis phase.

References
1. Cinza, Peronace, Giovanni Matera, Luisa Galati, Aida Giancotti, Giorgio Settimo Bareca, Angela Quirino, Maria Carla Liberto, Alfredo Focà
IL-35 and soluble CD14 subtype might be useful prognostic markers in critical septic patients Critical Care 2016, 20(Suppl 3):P24
2. Matera G, Quirino A, Peronace C, Settembre P, Marano V, Loria MT, Marasco N, Galati L, Bareca GS, Giancotti A, Amantea B, Liberto MC, Focà A. Soluble CD14 Subtype-A New Biomarker in Predicting the Outcome of Critically Ill Septic Patients. Am J Med Sci. 2017, 353(6):543-551

P28
To reduce the mortality in septic shock could require not only Polymyxin B immobilized fiber column direct hemoperfusion therapy also other treatment
Masash Osaka, Kazuma Shibahara, Makiko Saito, Miho Tsunoda, Mira Kang, Takuya Oshiro, Noriko Saito, Munekazu Takeda, Arino Yaguchi
Department of Critical Care and Emergency Medicine, Tokyo Women’s Medical University, Tokyo, Japan
Correspondence: Arino Yaguchi (ayaguchi@twmu.ac.jp)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P28

Background
Polymyxin B immobilized fiber column direct hemoperfusion (PMX-DHP) (TorymyxinTM, Toray Medical Co., Ltd., Tokyo, Japan) treatment has recently been shown to reduce their mortality in some populations in septic shock as a result of a randomized placebo-controlled trials (such as EUPHRATES trial), although it did not reach statistical significance of primary endpoint.

Objectives
Our hypothesis is not only to PMX-DHP therapy might also other therapies might need to improve the mortality in septic shock.

Methods
From November 2014 to December 2017, all adult patients treated with PMX-DHP and EAA (Endotoxin Activity Assay) showed ≥ 0.60 EAA units at pre-treatment of PMX-DHP in our medicosurgical ICU of university hospital were included in this retrospective study. Patients were divided into two groups, 1) patient with ≥ 10 MOD score and 2) patient with < 10 MOD score. EAA between before and after PMX-DHP therapy, SOFA score, P/F ratio, mean arterial pressure (MAP) at pre-treatment of PMX-DHP, platelet counts, total bilirubin, creatinine, age, sex 28 day mortality and 90 day mortality were compared between two groups. Patients’ data were collected from medical archives. Values were expressed as mean ± SD. Data was analyzed by chi-square test and Mann-Whitney U test. P values less than 0.05 were considered significant.

Results
Twenty-three patients (12 men, 11 women; age [mean 66.5 ± 13.0]) were included. SOFA score, MAP, P/F ratio, platelet counts, creatinine, 28-day mortality and 90-day mortality were significantly differences between patient s with ≥ 10 and with < 10 MOD score (16.3 ± 2.0 vs. 7.8 ± 3.5, 55.1 ± 3.9 vs. 70.7 ± 15.9, 127.1 ± 56.3 vs. 293.6 ± 157.6, 7.3 ± 4.8 vs. 16.3 ± 11.6, 3.4 ± 1.7 vs. 1.1 ± 1.4, 75% ± 27%, 75% ± 53%, p < 0.05, respectively). EAA units between before and after PMX-DHP therapy, total bilirubin, age, and sex did not show significant differences (0.75 ± 0.1 vs. 0.72 ± 0.1, 0.56 ± 0.26 vs. 0.44 ± 0.17, 2.0 ± 2.4 vs. 1.5 ± 2.1, 58.6 ± 12.0 vs. 66.5 ± 13.0, 75% ± 40%, p > 0.05, respectively).

Conclusions
The present study shows PMX-DHP therapy decreased EAA units after that treatment. However, severe organ dysfunctions, such as coagulopathy, AKI or ARDS, are complicated, only removal of endotoxins does not contribute to the mortality. Not only PMX-DHP therapy but also other treatment could be required to improve the mortality.

P29
Malnutrition and its clinical outcomes among sepsis patients admitted at Kigali university teaching hospital- Rwanda
Mushuru Evariste1, Cameron Page2, Tim Walker3
1Department of internal medicine, University teaching hospital/school of medicine and health sciences/University of Kigali, Kigali, Rwanda;
2University Hospital of Brooklyn, SUNY Downstate Medical Center, 450 Lenox Road, Brooklyn, NY 11226, USA; 3Calvary Mater Hospital, University of Newcastle, New South Wales, Australia, 2298
Correspondence: Mushuru Evariste (museva15@yahoo.fr)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P29

Background
Malnutrition has been associated with high mortality and prolonged hospital stay in other populations [1,2]. The impact of malnutrition among sepsis patients in Rwanda has not yet been studied. This study aimed to study malnutrition associated outcomes in sepsis patients admitted at Kigali university teaching hospital (CHUK)- Rwanda.

Materials and methods
We screened 239 consecutive patients with sepsis who were admitted at CHUK from January 2016 through February 2016, 2 subjects were excluded (one withdrew consent and another was found to be pregnant). Using the Subjective Global Assessment (SGA) tool, we classified patients as well-nourished or as suffering from moderate or severe malnutrition. Patients’ anthropometric data, socio-economic and clinical data on sepsis were collected using a pre-established questionnaire. Clinical data were collected using patient’s files whereas data on weight loss, appetite, functional status, were completed through patient’s interview or next of kin for patients who were unable to communicate at the time of data collection.

Results
Of 237 total patients, 90(38%) patients were malnourished, with 64(27%) having moderate malnutrition and 26(11%) having severe malnutrition. The prevalence of malnutrition was higher in males as compared to females (47.3% vs 32.2%, p=0.020). 47 (19%) patients had known positive HIV serology and this was associated with
malnutrition (p=0.005), 31(34.4%) patients were HIV negative. Malnourished patients lost on average 1.1kg during their hospital stay and well-nourished patients lost 0.6kg on average and the difference was statistically significant (p=0.003). Malnourished patients had longer hospital stay when compared to well-nourished patients, with a difference of 12.3days (28.7days for a malnourished patient vs 16.4days for a well-nourished patient (p<0.001). The likelihood of dying in malnourished patients is 2.3 times higher, as compared to normal patients (OR = 2.3, 95%CI: 1.25-2.49, p= 0.008).

Conclusions
Malnutrition among sepsis patients is common and is associated with prolonged hospital stay and high mortality. Further research is necessary to determine if early screening and improved management can improve these outcomes.

Acknowledgements
1.University of Utah which partially financed the study
2.Kigali University Teaching Hospital where the study was conducted

References
1. Allison SP. Malnutrition, disease, and outcome. Nutrition 2000 Jul; 16(7-8): 590–3
2. Kristina N., Claude P., Herbert L., Matthias P. Prognostic impact of disease-related malnutrition. Clinical Nutrition (2008)27,5–15

P30
CYP1A1-12(S)HETE-JNK-AP-1 signaling axis strengthens inflammatory responses in overactivated macrophages of sepsis
Lixing Tian, Xiaoyuan Ma, Xiaoying Zhou, Qi Huang, Junyu Zhu, Li Luo, Wanqi Tang, Wei Ma, Jing Yu, Xue Yang, Jun Yan, Huaping Liang
State Key Laboratory of Trauma, Burn and Combined Injury, Research Institute of Surgery, The Army Medical University, Chongqing, People’s Republic of China
Correspondence: Lixing Tian (tlxtmmu@163.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):p30

Background
Cytochrome P450 1A1 (CYP1A1), a kind of hydroxylase, plays a critical role in oxidative stress injury and mycoplasma infection. However, the relationship between CYP1A1 and inflammation, especially sepsis, remains poorly understood.

Materials and methods
(1) Ex vivo experiments, peritoneal macrophages isolated from wild type or Ahr-deficient (Ahr-/-) mice were treated with lipopolysaccharide(LPS) or heat-killed E.coli, and the mRNA and protein levels of CYP1A1 were determined.
(2) CYP1A1-overexpression and CYP1A1-loss-enzymatic-function macrophages were adaptively transferred to wild type mice challenged by LPS and CLP to observe the survival and illustrate the molecular mechanism.
(3) The level of CYP1A1 in human peripheral blood monocytes (PBMCs), isolated from healthy and septic individuals, were also detected by qRT-PCR and LSCM.

Results
CYP1A1 was highly expressed in mice peritoneal macrophages challenged by both LPS and heat-killed E.coli. Moreover, CYP1A1 and inflammatory factors were aberrant highly expressed in LPS challenged peritoneal macrophages from Ahr-/- mice compared with that from Ahr+/+ mice. Using CYP1A1-overexpression RAW264.7 cells (CYP1A1/ RAW), we found that CYP1A1 could intensify macrophages inflammatory responses by up-regulating TNF-a and IL-6 through enhancing JNK/AP-1 (c-fos and c-jun) phosphorylation rather than NF-xB (p65 and p50) phosphorylation. We discovered that CYP1A1/Raw secreted more 12(S)-HETE, while 12(S)-HETE antibody could attenuate intensified inflammatory responses caused by CYP1A1 overexpression. Administering 12(S)-HETE alone into normal RAW264.7 cells could also reinforce inflammatory responses even without LPS stimulation. Furthermore, we showed that loss-of-enzymatic-function of CYP1A1 in macrophages impeded LPS induced JNK/AP-1 phosphorylation and inflammatory factors secretion due to impaired generation of 12(S)-HETE. Mice transferred with CYP1A1-overexpression but not with CYP1A1-loss-enzymatic-function macrophages were highly susceptible to LPS and CLP challenge. In addition, the CYP1A1 expression and 12(S)-HETE concentration levels were elevated in PMBCs from septic patients and had a positive correlation with Sequential Organ Failure Assessment (SOFA) score.

Conclusions
Altogether, these results revealed a novel signaling axis, namely CYP1A1-12(S)-HETE-JNK-AP-1, regulating macrophages inflammatory responses in sepsis, which could be a promising target for preventing and treating sepsis.

P31
12(S)-HETE: a potential biomarker for sepsis?
Qi Huang, Jun Yan, Liping Yang, Xinyu Wang, Junyu Zhu, Lixing Tian, Xiaoyuan Ma, Yu Sun, Kuan Liu, Xue Yang, Wei Ma, Huaping Liang
State Key Laboratory of Trauma, Burn and Combined Injury, Research Institute of Surgery, The Army Medical University, Chongqing, People’s Republic of China
Correspondence: Huaping Liang (13638536728@163.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P31

Background
12(S)-HETE is the metabolite of arachidonic acid catalyzed by 12-lipoxygenase or cytochromeP450, which is implicated in hepatic ischemia-reperfusion injury, tumor metastasis and diabetes etc. However, whether or not it is correlated with sepsis remains unclear.

Materials and methods
(1) 12(S)-HETE levels were determined in the supernatant of LPS-stimulated macrophages and in the plasma from mice injected intraperitoneally with LPS or faeces.
(2) Inflammatory mediator TNF-a, IL-6 were determined in the supernatant of macrophages and mice plasma stimulated with 12(S)-HETE, and the in vivo pro-inflammatory response of 12(S)-HETE was observed when it was simultaneously used with LPS (i.p) inducing septic mice.
(3) 12(S)-HETE, TNF-a, IL-6 plasma levels were detected in septic patients and healthy volunteers and their relationship with Sequential Organ Failure Assessment (SOFA) score was investigated.

Results
Our study showed that 12(S)-HETE production in LPS-activated macrophages was increased and its plasma level was elevated in septic mice induced by LPS or faeces (i.p) respectively. When added into macrophages culture system without LPS stimulation, 12(S)-HETE significantly enhanced the production of TNF-a, IL-6 in a dose-dependent manner. In vivo administration of 12(S)-HETE (i.p) also strengthened pro-inflammatory response and organs injury in septic mice, which is evidenced by increased TNF-a, IL-6 levels and more serious lung and liver pathological injury and lower survival rate. When compared with healthy control, the plasma levels of 12(S)-HETE, TNF-a, IL-6 were elevated in septic patients, and 12(S)-HETE concentrations of septic patients showed a significant positive correlation with SOFA score, (r=0.850, P<0.002).
Conclusion

It is suggested that 12(S)-HETE possesses pro-inflammatory effect and is positively correlated to SOFA score in septic patients, which might be a potential biomarker for the assessment of sepsis outcomes and the possible therapeutic target for the treatment of sepsis.

P32

Personalized approach to early prediction of infectious complications in patients with severe trauma

Viktor V. Moroz1,3, Artem N. Kuzovlev1,3, Ekaterina A. Boeva7, Alij K. Zhanataev7, Andrey D. Durnev7, Vasilly I. Reshetnyak7
1VA. Negovsky Research Institute of General Reanimatology of the Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitationology, Moscow, Russia; 2V.V. Zakusov Research Institute of Pharmacology, Moscow, Russia; 3A.I.Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.

Correspondence: Artem Kuzovlev (artem_kuzovlev@mail.ru)
Intensive Care Medicine Experimental 2018; 6(Suppl 1):P32

Background

The aim of the study was to develop a method for early personalized prognostication of the appearance of infection complications in patients with severe trauma and blood loss.

Materials and methods

28 patients with severe trauma were examined (15 men, 13 women; 35.3±13.2 y.o.). To assess the effect of hypoxia on DNA damage and processes of white blood cell (WBC) death victims were split into two groups, taking into account the values of 4 indices: capillary pO2, lactate, pH, BE. Group 1 - “Hypoxia” + “-” 18 victims (4 indexes represented hypoxia on admission); group 2 - “Hypoxia” - “-” 10 victims (4 indexes within the normal range). Two subgroups were distinguished in each group: infection “+” (13 patients in group 1 and 9 in group 2) and infection “-” (5 patients in group 1 and 1 in group 2). DNA damage in WBC as well as indirect apoptosis and necrosis of leukocytes were evaluated by DNA comet method. Analysis was done by epifluorescence microscope (Lomo, Russia, *200-400). Images of DNA comets were analyzed using the CASP 1.2.2 software. Percentage of DNA in the tail of the total amount of DNA in the comet was used as a quantitative indicator of DNA damage. Statistics was done by Microsoft Excel and Statistica 6.0; logistic regression was used.

Results

In trauma patients and hypoxia there was an increase in leukocytes death via apoptosis and necrosis, accompanied by an increase in single-, double-strand DNA breaks (DSB). On the 3rd day after trauma change in these indicators in group 1 differed between the infection “+” and infection “*” by the rate of infection complications developed on the 5th-7th day of follow-up.

On the 3rd day after the trauma level of necrotic [8.7 (2.3; 14.7)%], apoptotic DNA comets [4.3 (2.5; 7.2)%] and single-, DSB [27.3 (21.4; 32.5)%] in patients with the hypoxia and infection “*” was higher than in group with the hypoxia “+” and infection “*” [6.7 (4.5; 12.4%); 4.3 (2.6; 7.2%); 13.4 (10.2; 18.6%), respectively]. ROC analysis of the total score (necrotic DNA comets + apoptotic DNA comets + single-, DSB) obtained on the 3rd day after trauma in the group hypoxia “*” revealed that area under the ROC curve was 0.923 (sensitivity 100%, specificity 75.0%; cut-off value 47.3%). Values of the total indicator below 47.3% indicated a high risk of development of infection complications.

Conclusions

Method of early personalized prognostication of the development of infection complications in patients with severe trauma and hypoxia was proposed. It included determination of the index summing up the percentage of DNA-apoptotic comets, DNA-necrotic comets and single-, double-strand DNA breaks of leukocyte.

P33

Identification of endogenous bacteriophages in patients with bacteremia and sepsis - an observational study

Sergey S. Petrikov1, Aslan K. Shabanov1, Tatiana V. Chernenkaya1, Elena B. Lazareva1, Natalia V. Evokimova1, Evgeny I. Zihienkov1, Artem N. Kuzovlev2, Arkady M. Goloubiev2, Andrey Grechko2

1N.V. Sklifosofsky Research Institute of Emergency Medicine, Moscow, Russia; 2V.A. Negovsky Research Institute of General Reanimatology of the Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitationology, Moscow, Russia; 3OOO SPC “MicroMir”, Moscow, Russia.

Correspondence: Artem Kuzovlev (artem_kuzovlev@mail.ru)
Intensive Care Medicine Experimental 2018; 6(Suppl 1):P33

Background

There are still limited data on the role of human endogenous bacteriophages in the prevention and treatment of infectious complications and sepsis in critically ill patients. The aim of this study was to investigate into the influence of endogenous bacteriophages on the mortality in intensive care unit patients with bacteremia and sepsis.

Materials and methods

25 intensive care unit patients with severe combined trauma were enrolled in this observational single-center study (8 women, 17 men; 48.3±18.3 y.o.). 28 blood samples were collected. Blood cultures were performed using an automated Bac-tec-9050 blood culture analyzer (Becton Dickinson, USA). Identification of the isolated microorganisms was carried out using an automatic analyzer WalkAway-40 (Beckman Coulter, USA). In order to isolate endogenous bacteriophages patients were sampled for blood and urine cultures. Proceeding of bacteriophages was performed by means of traditional virological methods. Bacteriophages extracted from the lysis zones after spot testing were examined on an electron microscope JEOl-1011 (Japan). Statistics was done by Microsoft Excel and Statistica 6.0, X2 criterion was used.

Results

Out of 25 patient’s bacteriophages were isolated in 10. Blood microbiology was: in 4 cases Klebsiella pneumoniae, in 3 - Acinetobacter sp., in 2 - Staphylococcus spp., 1 case of S. aureus and Enterococcus faecalis. In the group of patients who had their own endogenous bacteriophages 4 people died (40%). At the same time 2 patients had their own phages identical to the isolated microorganisms (Staphylococcus aureus and S. epidermidis) which were then eliminated. Later on these patients isolated strains of K. pneumonia to which endogenous phages were absent and patients died due to this infection. Out of 15 patients who did not have endogenous bacteriophages 9 (60%) died (p <0.002). Blood cultures in these 15 patients were: 5 cases - S. aureus, 2 - Staphylococcus sp., 5 - K. pneumonia, 2 - Acinetobacter sp. and in 1- Enterobacter aerogenes.

Conclusions

Endogenous bacteriophages influence the mortality of trauma patients with bacteremia and sepsis; mortality was significantly higher in the absence of endogenous bacteriophages (p <0.002).

P34

Inhibition of sphingosine kinase 1 for protection of gut barrier function in sepsis

Jeffery Ho, Stephen Liang, Xiaodong Liu, Lin Zhang, William KK Wu, Matthew TV Chan, Czarina CH Leung

Department of Anaesthesia and Intensive Care, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.

Correspondence: Czarina CH Leung (czarinaleung@cuhk.edu.hk)
Intensive Care Medicine Experimental 2018; 6(Suppl 1):P34

Background

The intestinal epithelium is a continuous single-cell layer separating the sterile bloodstream from the intestinal lumens. Accumulating evidence suggests that this barrier could be substantially impaired during severe systemic inflammation. Importantly, the severity of derangement of intestinal permeability in critically ill patients predicts subsequent development of multiple organ failure and its regulation by host factors remains unclear. Finding ways to maintain the
intestinal epithelial integrity is one of the major directions to improve the clinical outcome of sepsis.

Materials and methods
We performed cecal-ligation and puncture on CS78L/6 mice to induce polymicrobial sepsis. Animals undertook either sham surgery with saline injection, CLP with N,N-dimethylsphingosine (a potent inhibitor of sphingosine kinase 1), or CLP with saline injection. At 20h, the animals were orally fed with 4kDa fluorescein-dextran (FITC). At 24h after surgery, we collected blood and harvested ileal tissues for molecular characterization, including transcriptomic analysis.

Results
Of septic mice, intestine exhibited remarkable pathological changes, including increased epithelial apoptosis, reduced expression of tight junction proteins, and elevated serum FITC level. Transcriptomic profiling revealed that sphingosine kinase 1 increased more than six-fold after sepsis-induction. Pathway enrichment analysis revealed significant pathways pertinent to pro-inflammatory response. Animals with pharmacological inhibition using N,N-dimethylsphingosine had lower level of serum FITC, less severe sepsis symptoms and lower total bacterial DNA in the blood.

Conclusions
Inhibition of sphingosine kinase 1 may be a therapeutic strategy for preventing gut barrier dysfunction in sepsis. Further preclinical studies will be needed to confirm the beneficial effect in prior to clinical trials.

Acknowledgements
This study was funded by Health and Medical Research Fund of Hong Kong SAR (05160746; 16151002) and Australian and New Zealand College of Anaesthetists (18/019).

P35
Prognostic modeling of inflammatory correlates of mortality and persistence in complicated S. aureus bacteremia
Alessander O. Guimaraes 1
1Department of Biomarker Discovery, Genentech, Inc., South San Francisco, CA, USA; 2Division of Infectious Diseases, Duke University, Durham, NC, USA; 3Division of Infectious Diseases, Duke University, Durham, NC, USA.
†The significance of a correlation does not imply causation.

Background
P35
Prognostic modeling of inflammatory correlates of mortality and persistence in complicated S. aureus bacteremia
Alessander O. Guimaraes 1
1Department of Biomarker Discovery, Genentech, Inc., South San Francisco, CA, USA; 2Division of Infectious Diseases, Duke University, Durham, NC, USA; 3Division of Infectious Diseases, Duke University, Durham, NC, USA.
†These authors contributed equally to this work.

Correspondence: Carrie Rosenberger (rosenberger.carrie@gene.com) Intensive Care Medicine Experimental 2018, 6(Suppl 1):P35

Dysregulated inflammatory responses can lead to host-driven seque- lae such as sepsis, as well as an immune response not optimally tailored for bacterial clearance. Heterogeneity in the host response to invasive bacterial infection suggests that specific biomarker signatures could be utilized to differentiate patients prone to severe disease, thereby facilitating earlier implementation of more aggressive therapies. To further elucidate the inflammatory correlates of poor clinical outcomes in bacteremic patients, we evaluated the association between a large panel of blood proteins at initial presentation of bacteremia and disease severity outcomes.

Materials and methods
We conducted an observational study (n=32) to evaluate the prognostic value of 64 circulating protein biomarkers for mortality or persistent bacteremia (defined as positive blood cultures for >5 days) in patients with S. aureus bloodstream infections. Prioritized biomarkers were evaluated in a case-control study of 156 patients with S. aureus or Gram-negative bloodstream infections using serum samples collected within 1-3 days of empiric antibiotic therapy.

Results
We identified 8 candidate biomarkers of inflammation and endothelial activation that were prognostic for mortality and relevant to both Gram-positive and Gram-negative bacteremia. Statistical modeling identified that the combination of the chemokines IL-8 and CCL2 had the best power to classify fatal outcome and was superior to routine clinical laboratory and demographic metrics. A distinct set of 3 serum proteins was elevated early in patients with delayed clearance of bloodstream infection, with high baseline IL-17A showing the strongest correlation with the duration of positive blood cultures and endovascular infection foci.

Conclusions
These results identify immune correlates of delayed clearance of bloodstream infection and mortality in patients treated with appropriate antibiotics. These biomarkers are being evaluated in a validation cohort to evaluate their clinical utility for distinguishing patients with the highest risk for treatment failure and potential for selecting patients for clinical trials.

P36
Pellino3 impacts sepsis-mediated IL1b secretion in peritoneal macrophages
Lauria Kuchler, Anrika Giegerich, Bernhard Brune and Andreas von Koettern
Institute of Biochemistry I – Pathobiocchemistry, Faculty of Medicine, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.

Correspondence: Lauria Kuchler (kuchler@biochem.uni-frankfurt.de) Intensive Care Medicine Experimental 2018, 6(Suppl 1):P36

Background
Autophagy plays a central role in controlling innate immune responses by degradation of proteins. Autophagic factors like p62/SQSTM1 directly interact with molecules of the Toll-like receptor 4 (TLR4) pathway [1], which is activated in macrophages in response to lipopolysaccharide (LPS) [2]. In this signaling cascade Pellino3 serves as an IRAK E3 ligase and scaffold protein [3]. Its autophagy-dependent degradation impairs the hyperinflammatory phase during LPS challenge by inhibiting TLR4 signaling and IL1b expression [4]. Based on these in vitro data, we want to translate this setting in an in vivo cecal ligation and puncture (CLP) mouse model to substantiate the modulation of Pellino3 expression during sepsis as a new strategy for the development of a therapy approach.

Materials and methods
We used cecal ligation and puncture (CLP) to induce polymicrobial sepsis in wildtype mice to monitor Pellino3 expression. 6h/24h/48h following sepsis induction peritoneal macrophages and peritoneal fluid were harvested. Pellino3 and IL1b mRNA were analysed by RT-PCR. Pellino3 as well as LC3, p62 and pro-IL1b protein expression was elucidated by western analysis. IL1b levels in the peritoneal fluid were determined by cytometric bead array (CBA) via FACS analysis.

Results
We observed an initial increase of Pellino3 protein expression in peritoneal macrophages of wildtype mice after 24 h following CLP. This is accompanied by an increase of LC3-II, suggesting autophagic inhibition, and an increase in pro-IL1b. Comitantly, IL1b secretion in the peritoneal fluid is elevated. 48h after CLP Pellino3 is degraded, most likely due to increased autophagy as shown by simultaneously degradation of LC3-II. In lysates of peritoneal macrophages pro-IL1b protein expression is decreased and consequently in supernatants of these cells IL1b is attenuated.

Conclusions
Our in vivo data confirmed our in vitro findings of a correlation of Pellino3 and its degradation, impairing IL1b expression and secretion. The proof that autophagic processes are involved in Pellino3 degradation is still elusive in the mouse in vivo model. Therefore, experiments in autophagy-deficient mice using a p62-knockout model are planned for the near future. Moreover, the induction of autophagy at different timepoints during sepsis progression will help to confirm the mechanism. Since an overwhelming proinflammatory response is a main problem during sepsis, targeting Pellino3 by considering the knowledge of autophagy induction should be approached and extended in the future as a new therapy regime.
The effects of compounds on PPAR were assessed by mass spectrometry. To verify the potential modulating compounds were tested in cell viability assays. The intracellular transactivation assays in human cell lines. Cytotoxic effects of promiscuous in vitro were further investigated for their in vivo pharmacokinetic properties. Based on their in vitro properties, promising compounds were sized and kinetically characterized in vitro using PPAR-mediated modeling was performed. Potential candidates were synthesized and kinetically characterized in vitro using PPAR-dependent transactivation assays in human cell lines. Cytotoxic effects of promising compounds were tested in cell viability assays. The intracellular accumulation of suitable compounds in the same cell lines was assessed by mass spectrometry. To verify the potential modulating effects of compounds on PPAR target genes, gene expression was studied using quantitative real-time polymerase chain reaction (qPCR). Based on their in vitro properties, promising compounds were further investigated for their in vivo pharmacokinetic properties. Compounds fulfilling in silico, in vitro and in vivo requirements were finally tested in the mouse CLP sepsis model.

Results
In an initial screen, T-10017 was identified, from structurally related chemical compounds, as a potential lead compound for a new class of competitive, reversible PPAR antagonists. In the mouse CLP sepsis model, administration of T-10017 nanoparticles led after 48 h to a significant improvement in the survival of septic mice, compared with control mice, treated with unloaded nanoparticles. Starting from T-10017, we further optimized the compound properties by chemical modification, including agonistic and antagonist characteristics, solubility and stability, resulting in two derivatives with markedly improved in vitro and in vivo properties.

Conclusions
Compounds from our new class of SPPARMs are significantly effective in the treatment of murine sepsis. These compounds competitively inhibit PPARdependent T cell depletion, help to maintain immune competence, facilitate the controlled therapeutic regulation of hypoinflammation and thus, reduce severity and mortality of sepsis.

Acknowledgements
This research was supported by the research funding program Landes-Offensive zur Entwicklung wissenschaftlich-ökonominischer Exzellenz (LOEWE) of the State of Hesse, Germany, the Else Kröner-Fresenius foundation training program “Translational Research Innovation – Pharma” (TRIP) and the Collaborative Research Center 815 “Redox-Regulation” (SF815).

References
1. Soller M, Tautenhahn A, Brüne B, Zacharoek K, John S, Link H, von Knethen A. Peroxisome proliferator-activated receptor gamma contributes to T lymphocyte apoptosis during sepsis. J Leukoc Biol 2006, 79:225-234.
2. Schmidt MV, Paulus P, Kuhn AM, Weigert A, Morbitzer V, Zacharoek K, Kempf VA, Brüne B, von Knethen A. Peroxisome proliferator-activated receptor γ-induced T cell apoptosis reduces survival during polymicrobial sepsis. Am J Respir Crit Care Med 2011, 184:64-74.
3. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002, 41:6640-6650.
4. Knep T, Fleisch D, Kuchler L, Sha LK, Giegerich AK, Kuchler L, Sha LK, Knape T, Heide H, Wittig I, Behrend C, Brüne B, and von Knethen A. Autophagy-dependent PEL1 degradation inhibits proinflammatory IL-1β expression. Autophagy 2014, 10(11): 1953–1962.

P37
Improved selective peroxisome proliferator-activated receptor gamma modulators (SPPARMs) for treatment of sepsis
Tilo Knape1, Victor Hernandez-Olmos1, Daniel Flesch2, Mario Wurpglic2, Eugen Proschak1, 2, Jan Heering1, Mukul Ashitari1, Matthias G Wacker1,1, Manfred Schubert Zsilavecz2, Dieter Steinhei1,1, Bernhard Brüne1,4, Nerea Ferreiros-Bouzaiz1,5, Monica Villa Nova1, Sandra Labocha1, Michael J Parnham1, Andreas von Knethen1,4
1Branch for Translational Medicine and Pharmacology TIP, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt, Germany, 2Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany, 3Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt, Germany, 4Institute of Clinical Pharmacology, Goethe University Frankfurt, Frankfurt, Germany, 5Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt, Germany
Correspondence: Tilo Knape (tiloknape@ime.fraunhofer.de)

Background
Peroxisome proliferator-activated receptor gamma (PPARγ) has been shown to play a crucial role in immunosuppression during sepsis. Activated PPARγ is upregulated in T cells of septic patients, sensitizing these cells to PPARγ dependent apoptotic depletion [1]. In the mouse cecal ligation and puncture (CLP) sepsis model, both T cell-specific PPARγ gene knockout and systemic pharmacological PPARγ antagonism by GW9662 improved survival [2, 3]. As GW9662 is not suitable for therapeutic use in humans, we developed and improved a new class of selective PPARγ modulators (SPPARMs) for use in the treatment of sepsis in humans [4].

Materials and methods
To design improved SPPARMs, initial three-dimensional computational modeling was performed. Potential candidates were synthesized and kinetically characterized in vitro using PPARγ-dependent transactivation assays in human cell lines. Cytotoxic effects of promising compounds were tested in cell viability assays. The intracellular accumulation of suitable compounds in the same cell lines was assessed by mass spectrometry. To verify the potential modulating effects of compounds on PPAR target genes, gene expression was studied using quantitative real-time polymerase chain reaction (qPCR). Based on their in vitro properties, promising compounds were further investigated for their in vivo pharmacokinetic properties. Compounds fulfilling in silico, in vitro and in vivo requirements were finally tested in the mouse CLP sepsis model.

P38
The process of septic shock is attenuated by the intravenous administration of peptide VSAK: A FDG-PET study
Ismael Luna-Reyes1, Erendira Pérez-Hernández2, Miguel Ángel Avila-Rodríguez2, Jaime Mas-Oliva1
1Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, México, 2Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, México
Correspondence: Jaime Mas-Oliva (jmas@fc.unam.mx)

Background
The development of an uncontrolled inflammatory response is considered the main responsible of the most deleterious effects during severe sepsis and septic shock, that finally can lead to the condition known as Multiorgan Dysfunction Syndrome (MODS). The inflammatory response is triggered by pathogen derived molecules, mainly lipopolysaccharides (LPS). LPS and other pathogen molecules are released in early stages of sepsis and recognized by Pattern Recognition Receptors (PRR), directly involved in the initiation of the inflammatory response. In previous work, we have demonstrated in vitro and in vivo that VSAK, a peptide derived from the last eighteen amino acids of the carboxy-end segment of CETPI, considered an isoform of the cholesteryl-ester transfer protein (CETP) [1], is able to bind LPS and therefore, neutralize their harmful effects [2]. The present study provides additional evidence supporting the protective effects of VSAK administration in rabbits induced to a septic-shock-like state employing Positron Emission Tomography (PET).

Materials and methods
During the experiment, we used ten male Dutch dwarf rabbits provided by a local certified farm. Rabbits were randomly assigned to four experimental groups: 1) Control, 2) VSAK treatment, 3) LPS treatment, and 4) LPS+VSAK treatment. Immediately after, rabbits were administered 2-[18F]fluoro-2-deoxy-D-glucose (FDG) as the radiotracer and
monitored by PET. Each scan was performed during 70 minutes and PET data analysis carried out using spherical areas to define Volume of Interest (VOI) in order to reduce slight variations associated with differences in animal size.

Results

Figure 1 shows PET images from four representative rabbits, corresponding to each experimental group. In general, a marked decrease of glucose uptake can be observed in the LPS group. Results obtained from the normalized Standard Uptake Value (SUV) taking into account a spherical area of 5.5 mm in all four experimental groups are shown in Fig. 2. In all cases, SUV estimated in the first ten minutes was considered as 100% SUV and used to normalize individual data sets. A negative correlation between time and %SUV is observed in all experimental groups. The negative correlation is slightly more pronounced in the LPS group, decreasing up to 73.5% ±2.7 SEM at 70 minutes, while in the control group (83.43% ± 1.3 SEM), VSAK (83.99% ± 6.55 SEM) and VSAK-LPS (89.15% ± 2.09 SEM).

Conclusions

This study supports the potential in vivo use of peptide VSAK in order to neutralize the harmful effects of LPS and therefore avoid a metabolic dysfunction pattern during sepsis and septic shock [3].

Acknowledgements

We thank Blanca Delgado-Coello for expert technical assistance. We thank Conacyt for grant 255778 awarded to J.M-O.

References:

1) Alonso AL, Zentella-Dehesa A, Mas-Oliva J. Characterization of a naturally occurring new version of the cholesterol ester transfer protein (CETP) from small intestine. Mol Cellular Biochem 245: 173-182 (2003).
2) García-González V, Gutiérrez-Quintanar N, Mas-Oliva J. The C-terminus domain of CETP defines its function as a new plasma lipopolysaccharide-binding protein. Sci Rep, 5; 2015 (doi:10.1038/srep16091).
3) International Patent Application PCT/MX2014/000087
immunostaining and qPCR. Mirmimetics, antagonims and siRNAs were applied to establish the signalling pathway triggered during the infection [1].

Results
Following S. aureus infection, 58 endothelial miRNA were significantly down- and 35 significantly up-regulated, including the target of interest, miR-330 (p<0.05). Bioinformatic analysis of Next Generation RNA-seq data identified 102 potential miR-330 targets that were down-regulated following infection (p<0.005). Of interest were genes required for endothelial barrier integrity, including ADAM19 and ZO-1. 

During infection, miR-330 expression was inversely correlated with ADAM19 expression but not ZO-1 expression. Both S. aureus infection (p<0.05) and miR-330 overexpression (via miRmimetic transfection) in uninfected endothelial cells caused increased vascular permeability (p<0.005). siRNA analyses revealed that the increase in permeability was caused by an ADAM19 mediated VE-Cadherin depletion, initially triggered by the increase in miR330 expression.

Conclusions
Our results suggest that S. aureus infection leads to rapid increase in endothelial miR330, contributing to the loss of barrier integrity through down-regulation of the metalloproteinase ADAM19, which in turn leads to a decrease in essential junction protein VE-Cadherin. Preventing or blocking dysregulated miRNAs may hold promise as future therapeutics in the treatment of sepsis.

Acknowledgements
Prof. Steve Kerrigan, Prof. Ray Stallings, Dr. Olga Piskereva, Dr. Sudipto Das, Dr. Stephen Madden, Dr. Carolina Garciarena, Dr. John Nolan, Dr. Shane O’Grady , Mr. Tony McHale, Mr. Glenn Fitzpatrick, Ms. Unwana Umagha, Ms. Fajar Yousef.

References
1. McDonnell CJ, Garciarena CD, Watkin RL, McHale TM, McLoughlin A, Claes J, Verhamme P, Cummins PM, Kerrigan SW. Inhibition of major integrin alphaVbeta3 reduces Staphylococcus aureus attachment to sheared human endothelial cells. J Thromb Haemost, 2016. 14(12): p. 2536-2547.
2. McHale, TM, Garciarena CD, Fagan RP, Smith SG, Martin-Loches I, Curley GF, Fitzpatrick F, Kerrigan SW. Inhibition of Vascular Endothelial Cell Leak Following Escherichia coli Attachment in an Experimental Model of Sepsis. Crit Care Med, 2018.
3. Garciarena, CD, McHale TM, Martin-Loches I, and Kerrigan SW. Preventive and therapeutic value of blocking bacterial attachment to the endothelial alphaVbeta3 integrin with cilengitide in sepsis. Crit Care, 2017. 21(1): p. 246.
4. Watkin RL, Fitzpatrick GG, and Kerrigan SW. The Evolving Role of MicorRNAs in Endothelial Cell Dysfunction in Response to Infection. Semin Thromb Hemost, 2018. 44(3): p. 216-223.

P40 Stabilization of the vascular endothelium prevents bacterial spread in a rat pneumonia model of sepsis
Sinéad Hurley1, Eric Rogers1, Fidelma Fitzpatrick2, Ger Curley3, Steve Kerrigan1
1Cardiovascular Infection Research Group, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland; 2Department of Microbiology, RCSI, Beaumont Hospital, Dublin, Ireland; 3Anaesthesia and Critical Care, RCSI, Beaumont Hospital, Dublin, Ireland
Correspondence: Sinéad Hurley (sineadhurley@rcsi.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P40

Background
Sepsis is associated with severe vascular endothelial cell dysfunction which rapidly leads to dysregulation of normal systemic hemostasis and vascular reactivity triggering widespread tissue oedema. Although this process is considered central to the progression to organ failure during sepsis there are no therapeutic options available to treat or prevent endothelial dysfunction. Using an ex-vivo model of sepsis, we recently demonstrated that inhibition of major vascular endothelial cell integrin aVb3 prevented endothelial dysfunction induced by a number of sepsis pathogens by stabilising the vascular endothelium [1,2,3].

Aims
This study investigated the therapeutic usefulness of blocking aVb3 to control vascular endothelial cell dysfunction and stabilize the endothelium in an Escherichia coli induced rat pneumonia model of sepsis.

Materials and methods
Escherichia coli (CFT073) was delivered directly into the lungs, via a 14G cannula, of anaesthetized Sprague Dawley rats. Cilengitide, a specific aVb3 inhibitor, was administered intravenously (IV). Following progression to sepsis animals were sacrificed, organs were harvested and homogenised. Bacterial load in the spleen, liver, kidney, lungs and blood was assessed by viable count assay. Biomarker lactate was measured by ELISA. Vascular permeability was assessed using Evans blue dye.

Results
All animals were sacrificed at 24hrs. Bacterial counts (CFU/ml) in the blood (Fig. 1) and all major organs including the liver (Fig. 2A), kidney (Fig. 2B), spleen (Fig. 2C) and lung (Fig. 2D) were significantly lower in animals treated with cilengitide (control vs cilengitide treated, P<0.05). We next investigated if cilengitide was stabilizing the vascular endothelium thus preventing the dissemination of bacteria from the lung into the bloodstream. To test this, control non-infected animals were injected with Evan blue dye dye. These animals did not leak dye from their blood vessels as they maintain vascular integrity. In contrast animals that developed sepsis from the pneumonia displayed significant leakage from their blood vessels. Most strikingly, animals that developed pneumonia and were treated with cilengitide, failed to leak dye from their blood vessels suggesting that their endothelium was stabilised by the cilengitide thus reducing vascular permeability (Fig. 3) (untreated vs cilengitide treated, P<0.01). Finally and most critically, there was a significant reduction in the serum biomarker lactate in the cilengitide treated animals versus control animals (P<0.01) (Fig. 4), suggesting recovery.

Conclusions
Our results suggest that stabilizing the vascular endothelium by targeting the major endothelial cell integrin aVb3, may prevent the dissemination of bacteria to the blood and all major organs thus preventing progression to sepsis.

References
1. McDonnell CJ, Garciarena CD, Watkin RL, McHale TM, McLoughlin A, Claes J, et al. Inhibition of major integrin alphaVbeta3 reduces Staphylococcus aureus attachment to sheared human endothelial cells. J Thromb Haemost, 2016.14(12):2536-2547.
2. McHale TM, Garciarena CD, Fagan RP, Smith SG, Martin-Loches I, Curley GF, Fitzpatrick F, Kerrigan SW. Inhibition of Vascular Endothelial Cell Leak Following Escherichia coli Attachment in an Experimental Model of Sepsis. Crit Care Med, 2018.
3. Garciarena CD, McHale TM, Martin-Loches I, and Kerrigan SW. Pre-emptive and therapeutic value of blocking bacterial attachment to the endothelial alphaVbeta3 integrin with cilengitide in sepsis. Crit Care 2017.21(1):246-247
Fig. 1 (abstract P40). See text for description

Fig. 2 (abstract P40). See text for description

Fig. 3 (abstract P40). See text for description

Fig. 4 (abstract P40). See text for description
Background
In patients with sepsis general platelet hypo-responsiveness to exogenous agonists is associated with mitochondrial dysfunction [1], but the mechanisms of this are not yet known. As shown previously, aromatic microbial metabolites (AMM) may influence some mitochondrial functions [2]. The aim of this work is to evaluate the potential effect of aromatic metabolites on platelet aggregation in whole blood.

Materials and methods
We evaluated platelet aggregation (native and ASPItest) using the Multiplate platelet function analyzer (Roche), a total of 112 tests in whole blood of healthy volunteers (n = 11). Additives (20 μM) of AMM were selected in clinically significant dosage as shown early in patients with sepsis [3]. The following AMM: p-hydroxyphenylacetic (HPAA), phenylactic (PLA), phenylpropionic (PPA), benzoic (BA) acids were used at the first stage of the experiment (I). Complex mixtures of AMM were used at the second stage of the experiment (II); ∑PLA,HPAA,HPLA = 8.2 μM (II-A); ∑PLA, HPAA, HPLA = 17.5 μM (II-B); ∑PLA,HPAA,HPLA = 8.2 μM + PPA 1.4 μM (II-C) versus lipopolysaccharide (LPS). To compare the data, the Sign Test was used for the median.

Results
There were no statistically significant dose-dependent effects of AMM on native platelet aggregation. A significant decrease of median ASPItest under the influence of HPAA 15 μM and HPLA 30 μM were identified on 27% and 19.5% respectively, that presumably allows to regard these acids as cyclooxygenase (COX) and IIb/IIIa inhibitors antagonists. Complex mixtures had a more pronounced antiaggregation effect, especially the mixture II-C, comparable to the impact of LPS.

Conclusions
Aromatic microbial metabolites have the potential to affect platelet aggregation in vitro, which requires further study.

Acknowledgements
Supported by Russian Science Foundation Grant №15-15-00110.

References
1. Protti A. et al. Platelet mitochondrial dysfunction in critically ill patients: comparison between sepsis and cardiogenic shock. Crit Care. 2015 Feb 11;19:39.
2. Fedotcheva N. et al. Toxic effects of microbial phenolic acids on the functions of mitochondria. Toxicol Lett. 2008 Aug 28;180(3):182-8.
3. Beloborodova N et al. Normal level of sepsis-associated phenylcarboxylic acids in human serum. Biochemistry (Mosc). 2015 Mar;80(3):374-8.

P42
Quantifying multi-dimensional time-dependent abnormality of the host response in a cohort of patients suspected of sepsis
Ishan Taneja 1,2, Shai Dave Zhao 1, Ruqiang Zhu 1, Zhizhen Zhao 1, Sarah Formentini 1, Gregory Damhardor 1,2, Lucas Quinlan 1, James Kumar 3, Brad Weir 3, Karen White 3, Bobby Reddy Jr 1,2
1University of Illinois at Urbana Champaign, Champaign, IL, USA; 2Prenosis Inc, Champaign, IL, USA; 3Carle Foundation Hospital, Urbana Champaign, Champaign, IL, USA
Correspondence: Ishan Taneja (itaneja2@illinois.edu)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P42

Background
Sepsis is a syndrome defined as life-threatening organ dysfunction caused by a dysregulated host response triggered by an infection [1]. To date, numerous studies have captured aspects of the host response by measuring biomarkers pertinent to sepsis in human subjects [2,3]. Historically, the aim of these studies has been to demonstrate potential diagnostic or prognostic value of a set of biomarkers as opposed to specifically characterizing the degree of dysregulation of the host response. In our study, we sought to quantify the degree of dysregulation of the host response in a clinically relevant population in an intuitive and unbiased manner.

Materials and methods
In a cohort of 252 patients (Table 1) suspected of infection, we measured 15 biomarkers spanning various aspects of the host response as a function of time per patient. We specifically hypothesized that a multi-dimensional measure of time-dependent abnormality (termed the 'personalized immune score') could serve as a useful surrogate for quantifying dysregulation. We realize this may not capture the spirit of "dysregulation" but believe it could be a useful step forward toward that goal. We quantified multi-dimensional time-dependent abnormality through the formula 1/(x−y)^2 S−1(x−y), where x referred to a set/subset of 15 biomarker measurements at a given time point for a given patient, S referred to the covariance matrix of all biomarker measurements, and y referred to a set/subset of 15 biomarker measurements at discharge for a given patient (Fig. 1). We tested the association of relevant features/variables with respect to the following sepsis-related outcomes: ICD9/10 codes (sepsis/severe sepsis/septic shock), the sepsis-3 definition, clinically significant bacteremia, and hospital length of stay.

Results
We constructed three variants of the personalized immune score: one using all the biomarkers, one using only low signal biomarkers, and one using only high signal biomarkers. We also associated the association of each of the variants of the optimized personalized immune score with the respective biomarkers that composed each of the immune scores with respect to our outcomes of interest (Fig. 2A-C). We also compared the optimized personalized immune score with a patient's SIRS and SOFA score. (Fig. 2D). Raw p-values for each entry in the heatmap are reported in Tables 2, 3, 4 and 5, with the worst p-value (termed the 'bottleneck p-value') highlighted in red. In Fig. 3, we visualized the optimized personalized immune score as a function of time stratified by outcome.

Overall, there was a greater number of stronger associations between each outcome and all variants of the personalized immune score compared to that of any individual biomarker or EMR feature. Furthermore, the optimized immune score yielded stronger associations than any individual biomarker for three out of the four sepsis-related outcomes. Finally, when examining the bottleneck p-value in each table, all variants of the personalized immune score achieved the lowest value.

Conclusion
This study shows that a multi-dimensional measure of time-dependent abnormality of biomarkers that span various aspects of the host response could be a useful metric in evaluating the health state of a septic patient. Ultimately, we believe our work lays a foundation for quantifying the dysregulation of the host response in an unbiased manner.

References
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Anane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801.
2. Pierracos C, Vincent J-L. Sepsis biomarkers: a review. Crit Care [Internet]. BioMed Central; 2010 [cited 2018 Feb 8];14:R15. Available from: http://ccforum.biomedcentral.com/articles/10.1186/cc8872
3. Biron BM, Ayala A, Lomas-Neira JL. Biomarkers for sepsis: What is and might be? Biomark Insights. 2015;10:1–7.
Table 1 (abstract P42). See text for description

| Characteristic | All Patients (N = 252) |
|----------------|------------------------|
| Age, SD        | 56, 18                 |
| Gender         | 43% male, 57% female   |
| Comorbid Conditions |                   |
| CKD            | 16%                    |
| COPD           | 18%                    |
| Diabetes       | 30%                    |
| Cancer         | 26%                    |
| Positive Blood Culture |       |
| SOFA score, SD | 2.65, 2.59             |
| SIRS score, SD | 1.89, .94              |
| Sepsis-3       | 42%                    |
| ICD9/10 code for sepsis/severe sepsis/septic shock | 33% |

Table 2 (abstract P42). See text for description

| IL-6   | nCD64 | Pentraxin3 | PCT | Immune Score (Optimal) |
|--------|-------|------------|-----|------------------------|
| Sepsis | 0.027289 | 0.001975 | 0.002794 | 0.00149 | 0.000585 |
| Sepsis-3 | 0.000248 | 0.010245 | 0.004557 | 0.013857 | 1.43E-05 |
| Bacteremia | 4.24E-05 | 3.28E-05 | 8.72E-05 | 0.000136 | 5.17E-07 |
| Length of Stay | 3.58E-09 | 4.42E-10 | 6.10E-10 | 1.44E-15 | 1.73E-11 |

Table 3 (abstract P42). See text for description

| IL-6   | MIP-1a | G-CSF | MCP-1 | IP-10 | IL-1ra |
|--------|--------|-------|-------|-------|--------|
| Sepsis | 0.028914 | 0.909787 | 0.070411 | 0.103703 | 0.646896 |
| Sepsis-3 | 0.000267 | 0.915809 | 0.915809 | 0.103703 | 0.438506 |
| Bacteremia | 4.50E-05 | 0.082711 | 0.000267 | 1.99E-08 | 0.101414 |
| Length of Stay | 3.81E-09 | 0.000714 | 4.68E-05 | 2.02E-05 | 2.84E-09 |
| nCD64 | TREM-1 | RAGE | TRAIL | C5a | Protein-C |
| Sepsis | 0.002049 | 0.023998 | 0.260936 | 0.246073 | 0.822951 |
| Sepsis-3 | 0.010829 | 0.039883 | 0.157752 | 0.302052 | 0.284126 |
| Bacteremia | 3.43E-05 | 0.167446 | 0.199506 | 0.338874 | 0.496485 |
| Length of Stay | 4.89E-10 | 1.44E-05 | 1.80E-07 | 2.50E-05 | 7.90E-13 |
| Pentraxin3 | PCT | MMP-9 | Immune Score |
| Sepsis | 0.002939 | 0.011571 | 0.004303 |
| Sepsis-3 | 0.004842 | 0.014454 | 0.004303 |
| Bacteremia | 9.54E-05 | 0.00015 | 0.019903 | 1.23E-11 |
Table 4 (abstract P42). See text for description

|                | MIP-1α | G-CSF | MCP-1 | IP-10 | IL-1α | TREM-1 |
|----------------|--------|-------|-------|-------|-------|--------|
| Sepsis         | 0.292497 | 0.105219 | 0.036001 | 0.079042 | 0.066835 | 0.023998 |
| Sepsis-3       | 0.915809 | 0.070411 | 0.080203 | 0.037564 | 0.438506 | 0.039883 |
| Bacteremia     | 0.082711 | 0.000267 | 1.99E-08 | 0.010144 | 0.646896 | 0.167446 |
| Length of Stay | 0.000714 | 4.68E-05 | 2.02E-05 | 2.84E-09 | 0.000179 | 1.44E-05 |

Table 5 (abstract P42). See text for description

|                | SIRS (Initial) | SIRS (Initial-Final) | SOFA (Initial) | SOFA (Initial-Final) | Immune Score (Optimal) |
|----------------|----------------|----------------------|----------------|----------------------|------------------------|
| Sepsis         | 0.000121       | 0.000498             | 0.0083         | 0.0141               | 0.000585               |
| Sepsis-3       | 0.016297       | 0.015438             | 2.38E-22       | 4.11E-07             | 1.43E-05               |
| Bacteremia     | 0.119417       | 0.023998             | 0.00342        | 0.013683             | 5.17E-07               |
| Length of Stay | 0.006232       | 4.72E-07             | 0.000764       | 3.47E-10             | 1.73E-11               |

P43
Withdrawn

P44
Independent validation of a novel 12-mRNA score for sepsis prognosis

Timothy E Sweeney1, Melissa Remmel1, David Rawling1, Mark Eshoo1, Oliver Liesenfeld1, Charalambos Gogos2, Evangelos Giarmarlos-Bourboulis2
1Inflammatix, Inc, Burlingame, CA, USA; 2Department of Internal Medicine, University of Patras, Patras, Greece; 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
Correspondence: Timothy Sweeney (tim@inflammatix.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P44

Background
Improved prognostic and risk-stratification tools for patients with sepsis are needed both for improved clinical resource allocation and for prognostic enrichment in clinical trials [1]. We recently described a 12-mRNA host-response signature that, when measured quantitatively in whole blood, can accurately predict 28-day mortality [2]. In particular, we previously showed that the 12-gene ‘Stanford’ score has prognostic power both alone (AUROC mean 0.89, range 0.68-1.0 across 9 validation cohorts) and in combination with standard risk-stratification tools (such as SOFA) when linearly combined (mean boost in AUROC 0.10).

Materials and methods
Patient with sepsis according to Sepsis-2 criteria were enrolled at admission across multiple Greek ICUs. Whole blood was drawn into PaxGene RNA tubes at admission and frozen. For a pilot subset of 29 patients, RNA extraction (Qiagen QIAcube) was followed by measuring the 12-mRNAs using NanoString nCounter with a custom code-set. We combined expression levels of the 12 mRNAs into a single score as previously described [2]. Scores were used to directly calculate AUROCs, and also combined with clinical risk scores using linear regression trained locally.

Results
The 29 patients had a mean age of 68 +/- 13 years. By Sepsis-3 criteria, 9 had suspected infection but not sepsis; 11 had sepsis; 9 had septic shock. There were 20 survivors and 9 deaths. The AUROCs for predicting 28-day mortality were: qSOFA, 0.68 (95%CI 0.57-0.78); SOFA, 0.92 (95%CI 0.86-0.99); 12-mRNA score, 0.82 (95%CI 0.73-0.91). The AUROCs for linear combinations of qSOFA+12-mRNA score and SOFA+12-mRNA score were 0.86 (95%CI 0.78-0.94) and 0.96 (95%CI 0.91-1.0). 12-mRNA scores thus boosted AUROCs by 0.18 and 0.04, respectively, versus qSOFA and SOFA alone.

Conclusions
The 12-mRNA host-response signature continues to show validity for the prognosis of 28-day mortality in patients with sepsis in independent validation. Its ability to improve on standard prognostic scores such as qSOFA and SOFA is reconfirmed. A larger set of samples from the described cohort will be analyzed to increase the statistical power and overall validity of the results.

References
1. Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med. 2014;42(7):1714-21. doi: 10.1097/CCM.0000000000000325. PubMed PMID: 24717456.
2. Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM, et al. A community approach to mortality prediction in sepsis via gene expression analysis. Nat Commun. 2018;9(1):694. Epub 2018/02/15. doi: 10.1038/s41467-018-03078-2. PubMed PMID: 29449546; PubMed Central PMCID: PMC55814643.

P45
Cost effectiveness of emergency department use of a novel multi-mRNA assay for diagnosis and risk assessment of acute respiratory tract infections and sepsis

Ivana Stojanovic1, Jonathan Romanowsky2, Philippe Schuetz1,4, John Schneider1, Oliver Liesenfeld1, Timothy E Sweeney1
1Avalon Health Economics, LLC, Morristown, New Jersey, 07960, USA; 2Inflammatix Inc., Burlingame, California 94010, USA; 3Division of General and Emergency Medicine, University Department of Medicine, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland; 4Medical Faculty of the University of Basel, Basel, Switzerland
Correspondence: Timothy Sweeney (tim@inflammatix.com)
Intensive Care Medicine Experimental 2018, 6(Suppl 1):P45

Background
Emergency physicians currently rely on multiple imperfect tests to diagnose acute respiratory tract infections (ARTIs) and sepsis, leading to excess morbidity and mortality. A novel 30-host-gene PCR test (HostDx™ Sepsis by Inflammatix) identifies i) the likelihood of a bacterial infection, ii) the likelihood of a viral infection, and iii) the likelihood of sepsis and disease progression, in <60 minutes. This work examines the cost effectiveness of the HostDx Sepsis test for use in US healthcare system emergency departments (ED) for the assessment of ARTIs and sepsis.

Materials and methods
A decision-analytic simulation model compares the standard of care for patients assessed in the ED for ARTIs and suspected sepsis to a hypothetical care pathway with the HostDx Sepsis test. Analysis performed on expected costs and outcomes occurring during an ED visit...
for a hypothetical cohort of patients. Selected input outcomes were based on review of peer-reviewed articles. The 30-day outcomes considered in the study were expected cost per person presenting with ARTI or suspected sepsis to an ED, incremental cost per life-year saved, antibiotics days and hospital length of stay (HLOS).

Results

In the base-case scenario, across a cohort of 1,000, the HostDx Sepsis arm saves 10 lives/1,000 person-years and results in expected costs of $1,404/person less than the standard of care arm, reduced total antibiotics exposure by 1,097 days and 341 days of hospital stays comparing to the standard of care arm. Standard of care relied on empirical treatment, clinical judgment and multiple testing for bacterial and viral infections, with accuracy for bacterial, viral and mortality risk differentiation lower than that of HostDx Sepsis. In one- and two-way sensitivity analysis, model results were most sensitive to the HLOS, followed by the HostDx Sepsis test price, and length of antibiotics treatment.

Conclusions

The HostDx Sepsis arm demonstrated clinical utility and cost effectiveness versus the current standard of care arm. Improved care is reflected by fewer unnecessary antibiotic prescriptions and side effects, fewer admissions and shorter HLOS. Interventional studies are necessary to compare actual clinical and costs outcomes between current practice and that which incorporates HostDx Sepsis.

P46

Value of creatinine, prothrombin time and procalcitonin for predicting sepsis in patients with severe trauma

Xiao-yuan Ma, Hui-jian Jin, Qi Huang, Wei Ma, Hua-ping Liang
State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, The Army Medical University, Chongqing 400042, People’s Republic of China

Correspondence: Xiao-Yuan MA (M13658372627@163.com)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P46

Background

The main biomarkers for diagnosis and prognosis of sepsis are the following three categories: acute phase proteins, vascular related biomarkers, cytokines. However, it is still controversial whether these large numbers of biomarkers improves prediction of sepsis in trauma population. The aim of this study was to explore the predictive efficiency of new model based on creatinine, prothrombin time and procalcitonin in severe trauma patients.

Materials and methods

This was a retrospective observational analysis (reviewing the medical records) of 593 patients with severe trauma hospitalized in ICU of the Daping Hospital of Army Medical University from January 1, 2012 to December 31, 2017. Two models were established: Model-1, a logistic regression model with sepsis as the response value and mechanical ventilation, shock and APACHE-II at ICU admission as explanatory variables; and Model-2, the same variables as in Model-1, with creatinine, prothrombin time and procalcitonin added as explanatory variables. Data were processed with t test, chi-square test, and receiver operating characteristic (ROC) curves were determined for both two models. The discrimination indexes (C-index and Nagelkerke’s R2) and calibration curves for predicted sepsis versus observed sepsis were calculated for each model.

Results

There were 18527 trauma patients admitted at Daping Hospital of Army Medical University from January 1, 2012 to December 31, 2017. The study population of 593 cases with severe trauma hospitalized in ICU were ≥16 years old, incoming ICU within 24 hours after injury, the length of ICU stay ≥48 hours, ISS≥16, perfect clinical data, and without coexisting illness. 252 cases (42.50%) of 593 patients examined sepsis in hospital. In Model-2, creatinine, prothrombin time and procalcitonin were each a significant independent risk factor for sepsis diagnosis. The LR test comparing between Model-1 and Model-2 indicated significant improvement in Model-2 (P<0.001). Model-2 resulted in better values than Model-1 for discrimination indexes (C-index: 0.989 VS 0.941, Nagelkerke’s R2: 0.694 VS 0.570). ROC curves for Model-1 and Model-2 were 0.793 and 0.879 (P<0.001). Calibration improved the model fit: the mean absolute errors were 0.027 and 0.005 and the mean squared errors were 0.00069 and 0.00020 for Model-1 and Model-2, respectively.

Conclusions

In conclusion, the ability of a new model to predict sepsis in severe trauma patients improved following the addition of creatinine, prothrombin time and procalcitonin measured on ICU arrival within 24 hours as explanatory variables.

Acknowledgements

The author thanks ICU of Chongqing Daping Hospital for providing valuable information.

Sources of Funding This study was supported by the National Nature Science Foundation of China (NSFC, No. 81671906).

P47

Simplified sepsis-3 criteria using modified SOFA (MSOFA) score: A proposed sepsis diagnosis criteria in low-middle income country

Robert Sinto1, Suhendro Suwarto1, Khie Chen Lie1, Kunjoro Harimurti2, William Djauhari1, Dyoko Widodo1, Herdman T. Pohan1
1Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; 2Center for Clinical Epidemiology and Evidence Based Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia

Correspondence: Robert Sinto (rsinto@yahoo.com)

Intensive Care Medicine Experimental 2018, 6(Suppl 1):P47

Background

The complexity of sepsis-3 criteria based on Sequential Organ Failure Assessment (SOFA) score is underlined by the need to perform routine laboratory tests for fulfillment of the diagnosis criteria [1,2]. Modified SOFA (MSOFA) has been previously proposed as an alternative of SOFA score in predicting mortality of critical ill patients [3]. This study investigated the potential role of MSOFA score as a substitute of SOFA score in sepsis diagnosis criteria in hospital of low-middle income country, in comparison with quick SOFA (qSOFA) criteria.

Materials and methods

Prospective cohort study was conducted consecutively between April and November 2017 in suspected infection adult (aged 18 years and older) patients visiting Emergency Room of Cipto Mangunkusumo National Hospital, Indonesia. All variables from SOFA, MSOFA, qSOFA were collected. Patients were followed up until hospital discharge or death. Area under the receiver operating characteristic curve (AUROC) of modified criteria using increment of MSOFA, sepsis-3 diagnosis criteria (i.e. increment of two or more SOFA score consequent to the infection [1]) and qSOFA criteria were evaluated.

Results

Of 2695 patients screened, 1078 met the inclusion criteria and were included in the analysis. Mean age was 50 years (standard deviation 15.01 years). The two most common comorbidities were malignancy (29.5%) and diabetes mellitus (23.3%). Pneumonia (66.4%) and skin, soft tissue infection (20.4%) were two most common sources of infection. In-hospital mortality was 35.2%. The modified criteria using increment of MSOFA score showed good performance in predicting in-hospital mortality with an AUROC of 0.733 (95% CI 0.702-0.764). Sepsis-3 diagnosis criteria showed an AUROC of 0.752 (95% CI 0.723-0.782), while the AUROC of qSOFA criteria was 0.696 (95% CI 0.662-0.73) (Fig. 1). Using cut off ≥2, modified criteria using increment of MSOFA score showed sensitivity 74.7% and specificity 57.4%, while the sepsis-3 criteria showed sensitivity 75.5% and specificity 63.7%.

Conclusions

Simplified sepsis-3 criteria using increment of MSOFA score as a substitute of SOFA score shows a good performance and
could potentially be applied in hospitals of low-middle income
country.

Acknowledgements
This research was funded by Cipto Mangunkusumo National Hospital
Operational Research Grant 2017.

References
1. Singer M, et al: The third international consensus definitions for sepsis
and septic shock (sepsis-3). JAMA 2016, 315:801-810.
2. Seymour CW, et al: Assessment of clinical criteria for sepsis: for the third
international consensus definitions for sepsis and septic shock (sepsis-3).
JAMA 2016, 315:762-774.
3. Grissom CK, Brown SM, Kuttler KG, Boltax JP, Jones J, Jephson
AR, Orme Jr JF: A modified sequential organ failure assessment
score for critical care triage. Disaster Med Public Health Prep 2010,
4:277-284.

Fig. 1 (abstract P47). See text for description

Fig. 1 (abstract P48). Forest plots of AUC for (a) qSOFA and (b) SIRS
in predicting mortality

Fig. 2 (abstract P48). Forest plots of AUC for (a) qSOFA and (b) SIRS
in predicting composite outcomes (organ dysfunction or admission
to ICU)
Background
Sepsis (infection complicated by organ dysfunction) is associated with a dysregulated immune response. The mechanism of immune dysregulation is not well understood but impaired energy metabolism in circulating leukocytes is thought to play a role [1,2]. Here, to gain mechanistic insight into immune dysregulation, we measured leukocyte metabolism and apoptosis in infected patients who were at risk of developing sepsis.

Materials and methods
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood of healthy controls (n=8), low-risk (n = 6) and high-risk infection patients (n = 10). Low risk infection was defined as clinical suspicion of infection with a normal qSOFA score (qSOFA is a prediction index for the subsequent development of sepsis). High risk infection was defined as clinical suspicion of infection plus an increase of 2 points in qSOFA score. The PBMC metabolic profiles, total cellular reactive oxygen species (ROS) and the number of apoptosis cells were measured by Agilent Seahorse XF analyser (Agilent Technologies), DCFDA Cellular ROS Detection Assay (abcam) and Annexin V-FITC Apoptosis Detection kit (abcam), respectively. Total cellular ROS and apoptosis detection were further quantified by flow cytometry.

Results
The mitochondrial respiration in PBMC was significantly reduced in high risk infection patients as compared to healthy controls, especially in reserve capacity (maximal respiration and spare respiratory capacity). There was also a trend towards reduced mitochondrial respiration in low risk infection patients as compared to healthy controls (Fig. 1).

Conclusions
The metabolic switch to glycolysis, a normal compensatory response to mitochondrial suppression in infection, was not observed in the circulating leukocytes of patients with a higher risk for sepsis. This metabolic derangement was not related to the oxidative stress in the leukocytes. This novel finding reveals an unexpected level of complexity in the metabolic dysregulation of circulating leukocytes, thereby opening up a potential new avenue for further investigation.

References
1. Cheng SC, Scicluna BP, Arts RJW, Gresnigt MS, Lachmandas E, Giamarellos-Bourboulis EM, et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol 2016;17(4):406-13.
2. Park DW, Zmijewski JW. Mitochondrial dysfunction and immune cells metabolism in sepsis. Infect Chemother 2017;49(1):10-21.
The development of an online scenario-based module to improve the identification and treatment of sepsis in a large NHS Trust
Emma Mewse 1, Katie McFaul 1, Bhaveet Radia 2
1 Infection Department, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 2 Education, Training and Development Department, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Correspondence: Emma Mewse (Emma.Mewse@gstt.nhs.uk)

Intensive Care Medicine Experimental 2018, 6(Suppl 1): P50

Background
Sepsis causes morbidity and mortality. In the UK, sepsis causes 250,000 cases and 44,000 deaths annually [1]. Better diagnosis and treatment could save 11,000 lives and £160 million each year [2]. Sepsis 6 are interventions [1,3-4] which can reduce mortality by 50% if all components are implemented within 60 minutes [5]. Local audit of patients with suspected and confirmed sepsis reveals low compliance with these interventions. We sought to develop a teaching strategy to improve sepsis recognition and management. Traditional classroom-based teaching (TCBT) methods and an online module were developed and staff sepsis training evaluated. These teaching methods included a case-study approach encompassing all facets of sepsis recognition and management. We sought to evaluate the acceptability and effectiveness of each intervention.

Materials and methods
Current local, national and international guidelines informed development and subject matter of both TCBT and an online module. This module is available to all hospital employees via local intranet and mobile devices (Fig. 1). Both teaching methods were departmentally peer-reviewed and trialled in pilot clinical areas.

Defined outcomes were specified:
- Acceptability and effectiveness of TCBT and online teaching
- Definition of sepsis, septic shock, sepsis red flags, Sepsis 6 components, desired time to management of sepsis
- Individuals’ confidence in sepsis management in a post-teaching survey
- Ongoing collection of qualitative feedback

Results
1. TCBT- pre and post teaching results were recorded. There was a marked improvement in all areas specified including sepsis knowledge and confidence in sepsis management (Fig. 2).
2. Online module was well received by staff and was considered an effective and enjoyable way to learn. Data collection is ongoing, including the specified outcomes.

Conclusions
We have demonstrated benefits to staff sepsis knowledge from TCBT. Advantages of online teaching include availability,
minimal disruption to clinical care, a standardised approach and recordable outcomes. Online learning modules and TCBT can improve sepsis care and management. High-quality online modules can deliver sepsis training and ensure all staff have access to learning resources. Our data provides insights into the learning experience. Future work will compare TCBT and online teaching.

Acknowledgements
We thank the staff at Guy’s and St Thomas’ hospital for their participation.

References
1. Daniels R and Nutbeam T eds. The Sepsis Manual 4th edition 2017-2018. https://sepsistrust.org/. Accessed 7th February 2018.
2. Department of Health and Social Care. New action to reduce sepsis. London, 2015. https://www.gov.uk/government/news/new-action-to-reduce-sepsis. Accessed 5th January 2018.
3. Sepsis recognition, diagnosis and early management (NG51). National Institute Clinical Excellence, London, 2016. https://www.nice.org.uk/guidance/ng51. Accessed 27th June 2018.
4. Levy MM, Evans LE and Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018; https://doi.org/10.1007/s00134-018-5085-0. Accessed 21st June 2018.

5. Daniels R, Nutbeam T, McNamara G, and Galvin C. The sepsis six and the severe sepsis resuscitation bundle: a prospective observational cohort study. Emerg Med J 2011; 28:507-512. doi:10.1136/emj.2010.095067. Accessed 14th December 2017

Fig. 1 (abstract P50). Screenshot of module on mobile device and desktop

Fig. 2 (abstract P50). Questionnaire results pre/post teaching

P51
Withdrawn

P52
Withdrawn

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.